FGFR inhibitors and methods of use thereof

FGFR2 selective inhibitors, represented by Formula I and Formula I-1, address the limitations of pan-FGFR inhibitors by targeting FGFR2 specifically, improving treatment efficacy and safety in cancers with FGFR2 abnormalities.

JP2024156729AActive Publication Date: 2024-11-06RELAY THERAPEUTICS INC +1
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
JP2024117746
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-04-17
Filing Date
2024-07-23
Publication Date
2024-11-06
Estimated Expiration
2040-05-12

AI Technical Summary

Technical Problem

Current FGFR inhibitors, particularly pan-FGFR inhibitors, face challenges such as hyperphosphatemia due to their inability to selectively target FGFR1, limiting their dosage and efficacy in treating cancers with FGFR2 gene fusions, amplifications, or mutations, necessitating the development of FGFR2 selective inhibitors to mitigate toxicity and enhance treatment efficacy.

Method used

Development of compounds, such as those represented by Formula I and Formula I-1, which are FGFR2 selective inhibitors, designed to target and inhibit FGFR2 signaling pathways while minimizing effects on FGFR1, thereby reducing toxicity and enhancing therapeutic outcomes.

Benefits of technology

The FGFR2 selective inhibitors effectively treat disorders mediated by FGFR2, offering improved safety profiles and enhanced clinical responses in cancers with FGFR2 abnormalities by reducing off-target effects and hyperphosphatemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156729000001
    Figure 2024156729000001
  • Figure 2024156729000002
    Figure 2024156729000002
  • Figure 2024156729000003
    Figure 2024156729000003
Patent Text Reader

Abstract

To provide a FGFR inhibitor and a method of use thereof.SOLUTION: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of the disclosure, for example, a compound of formula I-1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Citation of Related Applications This application claims the benefit of U.S. Provisional Application No. 62 / 846,991, filed May 13, 2019; U.S. Provisional Application No. 62 / 993,957, filed March 24, 2020; and U.S. Provisional Application No. 63 / 011,469, filed April 17, 2020, each of which is incorporated by reference in its entirety. [Background technology]

[0002] background Fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, and FGFR4) are receptor tyrosine kinases consisting of an extracellular ligand-binding domain and an intracellular tyrosine kinase domain. Binding of FGF ligands leads to receptor dimerization and a conformational change in the intracellular domain, resulting in intracellular transphosphorylation of the kinase domain and intracellular tail. The phosphorylated residues serve as docking sites for adaptor proteins that promote downstream signaling cascades leading to cellular behaviors, including proliferation, survival, differentiation, migration, and angiogenesis. Unregulated FGFR signaling can occur through FGFR gene amplification or fusions, FGFR missense mutations, receptor overexpression resulting from epigenetic and / or transcriptional regulator dysregulation, or through signal transduction of FGF ligands in the tumor environment. FGFRs are expressed in many cell types. Thus, aberrant FGFR signaling has been implicated as a cause of tumorigenesis, tumor progression, and resistance to therapy across many tumor types (for a review of FGFR signaling, see N. Turner and R. Grose, Nat. Rev. Cancer 2010, 10:116-129; and references cited therein). Pan-FGFR1-3 inhibitors have produced clinical responses in many FGFR-related cancers, but precise targeting toxicity limits the dose of these inhibitors. One of the most common adverse effects of pan-FGFR inhibition is hyperphosphatemia. Regulation of phosphate reabsorption is mediated by FGFR3 and FGFR1. Therefore, FGFR-selective inhibitors that spare FGFR1 are needed (J. Gattineni et al., Am. J. Physiol. Renal Physiol. 2014, 306:F351-F358; X. Han et al., PLoS One 2016, 11:e0147845). Cancers harboring FGFR2 gene fusions and cancers with FGFR2 amplification and / or FGFR2 activating mutations have shown responses to pan-FGFR inhibition, but the low rate and duration of response suggest that toxicity is limiting. Thus, there is a need for FGFR2-selective inhibitor compounds and methods of using these compounds to treat cancer and other disorders. (For reviews of pan-FGFR1-3 inhibitors and clinical responses, see I.S. Babina and N.C. Turner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; and references incorporated herein.) [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] N.Turner and R.Grose, Nat.Rev.Cancer 2010,10:116-129 [Non-patent document 2] J. Gattineni et al.,Am.J.Physiol.Renal Physiol.2014,306:F351-F358 [Non-patent document 3] X. Han et al.,PLoS One 2016,11:e0147845 [Non-patent document 4] ISBabina and NCTurner,Nat.Rev.Cancer 2017,17:318-332 [Non-Patent Document 5] M.Katoh, Nat.Rev.Clin.Oncol.2019,16:105-122 Summary of the Invention [Means for solving the problem]

[0004] Abstract In some embodiments, the present disclosure provides compounds of formula I-1: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula I-1, Cy A , Cy 6 , L 6 , R 5 , and R W Each of the is as defined in the embodiments and classes and subclasses herein.

[0005] In some embodiments, the present disclosure provides a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein in Formula I, Cy 6 , L 6 , R 5 , R 7 , and R W Each of the is as defined in the embodiments and classes and subclasses herein.

[0006] In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of the present disclosure, e.g., a compound of Formula I-1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or diluent.

[0007] In some embodiments, the invention provides a method of treating an FGFR-mediated disorder, comprising administering to a patient in need thereof a compound of formula I, or a composition containing the compound. In some embodiments, the invention provides a method of treating an FGFR-mediated disorder, comprising administering to a patient in need thereof a compound of the present disclosure, e.g., a compound of formula I-1, or a composition containing the compound.

[0008] In some embodiments, the present invention provides a process for providing a compound of formula I, or a synthetic intermediate thereof. In some embodiments, the present invention provides a process for providing a compound of the present disclosure, e.g., a compound of formula I-1, or a synthetic intermediate thereof.

[0009] In some embodiments, the present invention provides processes for providing pharmaceutical compositions containing compounds of formula I. In some embodiments, the present invention provides processes for providing pharmaceutical compositions containing compounds of the present disclosure, e.g., compounds of formula I-1. DETAILED DESCRIPTION OF THE INVENTION

[0010] Detailed Description 1. General Description of Certain Embodiments of the Invention The compounds of the present invention, and pharmaceutical compositions thereof, are useful as inhibitors of FGFR2. In some embodiments, the present invention provides compounds of formula I-1: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula I-1: Cy A teeth, [ka] where [ka] is R 5 represents a bond to, and [ka] Cy 6 represents a bond to; R 5 -R 5A -L 5 -R 5B and; R 5A is R B where R 5A -L 5 -R 5B In addition, m examples of R 5C is replaced by; R 5B is hydrogen or R B where R 5B is n examples of R 5D is replaced by; Cy 6 is phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Cy is 6 -L 6 -R W In addition, p examples of R 6is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of A or R B where R 6 is the number of q examples in R C is replaced by; or R 6 Two examples of R 6 One example of R L One example of this is R 6 One example of R WA One example of this is R 6 One example of R 7a together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; R 8 is H, -NR2, halogen, -OH, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 9 is H, -NR2, halogen, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 10 is H or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; L 5 and L 6 each independently represents a covalent bond, or C 1~4wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~6 Cycloalkylene, 3- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; 3~6 Each of cycloalkylene, 3- to 6-membered heterocycloalkylene, and 5- to 6-membered heteroarylene is selected from one example of R A or C 1~6 aliphatic and optionally substituted; R WA , R WB , and R WC are independently hydrogen, deuterium, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R Ltogether with the atoms therebetween to form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of the w examples of R C is replaced by; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of R A or R B and u examples of R C is replaced by; or R 5C Two examples of R 5C One example of R 5D One example of, or R 5D two instances of R together with the atom between them form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is C is replaced by; R A each instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C and each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each of m, n, p, q, r, t, u, v, and w is independently 0, 1, 2, 3, or 4.

[0011] In some embodiments, the present invention provides a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula I: R 5 -R 5A -L 5 -R 5B and; R 5A is R B where R 5A -L 5 -R 5B In addition, m examples of R 5C is replaced by; R 5B is hydrogen or R B where R 5B is n examples of R 5D is replaced by; Cy 6 is phenylene or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 -L 6 -R W In addition, p examples of R 6 is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of A or R B where R6 is the number of q examples in R C is replaced by; or R 6 Two examples of R 6 One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; L 5 and L 6 each independently represents a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; R WA , R WB , and R WC are independently hydrogen, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is a ring formed by combining the atoms between them to form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of R A or R B and u examples of R C is replaced by; R A each instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C and each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4. 2. Compounds and Definitions

[0012] The compounds of the present invention include those generally described above and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, unless otherwise specified, the following definitions shall apply. For the purposes of this invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Edition. Furthermore, general principles of organic chemistry are described in "Organic Chemistry," Thomas Sorrell, University of Science, the entire contents of which are incorporated herein by reference. Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th Edition, eds. Smith, M.B. and March, J., John Wiley & Sons, New York: 2001. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. When a compound is described using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates.

[0013] The term "aliphatic" or "aliphatic group," as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted, hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic or bicyclic hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic (also referred to herein as "carbocyclic" or "alicyclic"), having one point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocycle") refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more units of unsaturation, but is not aromatic, and has one point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, straight-chain or branched, saturated or unsaturated, alkyl, alkenyl, alkynyl groups, and hybrids thereof (e.g., (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl).

[0014] The term "alkyl," as used herein, unless otherwise indicated, refers to a monovalent aliphatic hydrocarbon radical having straight-chain, branched-chain, monocyclic, or polycyclic moieties, or combinations thereof, which radical is optionally substituted on one or more carbons of the straight-chain, branched-chain, monocyclic, or polycyclic moiety, or combinations thereof, with one or more substituents on each carbon, and wherein the one or more substituents are independently selected from the group consisting of C1 to C6. 10Examples of "alkyl" groups include methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and norbornyl.

[0015] The term "lower alkyl" refers to C 1~4 " refers to a straight or branched chain alkyl group of the formula: Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0016] The term "lower haloalkyl" refers to a C alkyl group substituted with one or more halogen atoms. 1~4 The term "alkyl" refers to a straight or branched chain alkyl group.

[0017] The term "heteroatom" refers to oxygen, sulfur, nitrogen, phosphorus, or silicon (any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring (e.g., N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR + (as in N-substituted pyrrolidinyl)).

[0018] The term "unsaturated," as used herein, means a moiety having one or more units of unsaturation.

[0019] As used herein, the term "C 1~8 (or C 1~6 , or C 1~4 )) divalent saturated or unsaturated, straight or branched hydrocarbon chain" refers to straight or branched divalent alkylene chains, alkenylene chains, and alkynylene chains as defined herein.

[0020] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH) n -, where n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogens are replaced with a substituent. Suitable substituents include those described below for substituted aliphatic groups.

[0021] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with substituents. Suitable substituents include those described below for substituted aliphatic groups.

[0022] The term "halogen" means F, Cl, Br, or I.

[0023] The term "aryl," used alone or as part of a larger moiety, as in "aralkyl," "aralkoxy," or "aryloxyalkyl," refers to a monocyclic or bicyclic ring system having a total of 5 to 14 ring members, in which at least one ring in the system is aromatic, and in which each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring." In certain embodiments of the present invention, "aryl" refers to an aromatic ring system, including, but not limited to, phenyl, biphenyl, naphthyl, and anthracyl, which may bear one or more substituents.

[0024] The term "heteroaryl" or "heteroaromatic," as used herein, unless otherwise defined, refers to a monocyclic aromatic 5- to 6-membered ring containing one or more heteroatoms, e.g., one to three heteroatoms such as nitrogen, oxygen, and sulfur, a polycyclic ring system containing one or more heteroatoms, or an 8- to 10-membered polycyclic ring system, where at least one ring in the polycyclic ring system is aromatic and the point of attachment of the polycyclic ring system is through a ring atom on the aromatic ring. Heteroaryl rings can be attached to adjacent radicals through carbon or nitrogen. Examples of heteroaryls include, but are not limited to, furan, thiophene, pyrrole, thiazole, oxazole, isothiazole, isoxazole, imidazole, pyrazole, triazole, pyridine, pyrimidine, indole, and the like. For example, unless otherwise defined, 1,2,3,4-tetrahydroquinoline, when its point of attachment is through the benzo ring, is, for example: [ka] In the case of

[0025] The term "heterocyclyl" or "heterocyclic group," unless otherwise defined, refers to a saturated or partially unsaturated 3- to 10-membered monocyclic or 7- to 14-membered polycyclic ring system (including bridged or fused rings) containing 1 to 4 heteroatoms, such as nitrogen, oxygen, and sulfur. The heterocyclyl ring can be attached to the adjacent radical through either carbon or nitrogen.

[0026] The term "partially unsaturated" in the context of a ring refers to a monocyclic ring or a component in a polycyclic (e.g., bicyclic, tricyclic, etc.) ring system in which the component ring contains at least one degree of unsaturation in addition to that provided by the ring itself, but is not aromatic, unless otherwise defined. Examples of partially unsaturated rings include, but are not limited to, 3,4-dihydro-2H-pyran, 3-pyrroline, 2-thiazoline, and the like. When a partially unsaturated ring is part of a polycyclic ring system, the other component rings in the polycyclic ring system may be saturated, partially unsaturated, or aromatic, but the point of attachment of the polycyclic ring system is on the partially unsaturated component ring. For example, unless otherwise defined, 1,2,3,4-tetrahydroquinoline, when its point of attachment is through the piperidino ring, can be, for example: [ka] In the case of

[0047] , it is a partially unsaturated ring.

[0027] The term "saturated" in the context of a ring refers, unless otherwise defined, to a 3- to 10-membered monocyclic ring or a 7- to 14-membered polycyclic (e.g., bicyclic, tricyclic, etc.) ring system in which the component ring that is the point of attachment to the monocyclic ring or polycyclic ring system does not contain any additional degree of unsaturation beyond that provided by the ring itself. Examples of monocyclic saturated rings include, but are not limited to, azetidine, oxetane, cyclohexane, and the like. When a saturated ring is part of a polycyclic ring system, it may be saturated, partially unsaturated, or aromatic, but the point of attachment of the polycyclic ring system is on the saturated component ring. For example, unless otherwise defined, 2-azaspiro[3.4]oct-6-ene, when its point of attachment is through the azetidino ring, can be, for example: [ka] In the case of , it is a saturated ring.

[0028] The terms "alkylene," "arylene," "cycloalkylene," "heteroarylene," "heterocycloalkylene," and similar terms with the suffix "-ylene," as used herein, refer to divalently linked versions of the group that the suffix modifies. For example, an "alkylene" is a divalent alkyl group that is linked to the group to which it is attached.

[0029] As used herein, the term "bridged bicyclic" refers to any bicyclic ring system (i.e., carbocyclic or heterocyclic) that is saturated or partially unsaturated and has at least one bridge. As defined by IUPAC, a "bridge" is an unbranched chain of atoms, or a single atom, or a valence bond connecting two bridgeheads, where a "bridgehead" is any skeletal atom of the ring system that is bonded to three or more skeletal atoms (other than hydrogen). In some embodiments, a bridged bicyclic group has 7 to 12 ring members and 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include the groups described below, in which each group is attached to the remainder of the molecule at any suitable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents, such as those described for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclic rings include: [ka] Examples include:

[0030] As described herein, compounds of the invention may contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety have been replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be either the same or different at each position. Combinations of substituents envisioned by the present invention are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to compounds that are substantially unchanged when subjected to conditions that permit their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0031] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently: halogen; -(CH) 0~4 R ○ ;-(CH2) 0~4 OR ○ ;-O(CH2) 0~4 R ○ , -O-(CH2) 0~4 C(O)OR ○ ;-(CH2) 0~4 CH(OR ○ )2;-(CH2) 0~4 SR ○ ;-(CH2) 0~4 Ph (which is R ○ -(CH2) 0~4 O(CH2) 0~1 Ph (which is R ○ -CH=CHPh (which may be substituted with R ○ -(CH2) 0~4 O(CH2) 0~1 -pyridyl (which is R ○which may be replaced by); -NO2; -CN; -N3; -(CH2) 0~4 N(R ○ )2; -(CH2) 0~4 N(R ○ )C(O)R ○ ; -N(R ○ )C(S)R ○ ; -(CH2) 0~4 N(R ○ )C(O)NR ○ 2; -N(R ○ )C(S)NR ○ 2; -(CH2) 0~4 N(R ○ )C(O)OR ○ ; -N(R ○ )N(R ○ )C(O)R ○ ; -N(R ○ )N(R ○ )C(O)NR ○ 2; -N(R ○ )N(R ○ )C(O)OR ○ ; -(CH2) 0~4 C(O)R ○ ; -C(S)R ○ ; -(CH2) 0~4 C(O)OR ○ ; -(CH2) 0~4 C(O)SR ○ ; -(CH2) 0~4 C(O)OSiR ○ 3; -(CH2) 0~4 OC(O)R ○ ; -OC(O)(CH2) 0~4 SR ○ ; -SC(S)SR ○ ; -(CH2) 0~4 SC(O)R ○ ; -(CH2) 0~4 C(O)NR ○ 2; -C(S)NR ○ 2; -C(S)SR ○ ; -SC(S)SR ○ 、 -(CH2) 0~4 OC(O)NR ○ 2; -C(O)N(OR ○ )R ○ ; -C(O)C(O)R ○;-C(O)CH2C(O)R ○ ;-C(NOR ○ )R ○ ;-(CH2) 0~4 SSR ○ ;-(CH2) 0~4 S(O)2R ○ ;-(CH2) 0~4 S(O)2OR ○ ;-(CH2) 0~4 OS(O)2R ○ ;-S(O)2NR ○ 2;-(CH2) 0~4 S(O)R ○ ;-N(R ○ )S(O)NR ○ 2;-N(R ○ )S(O)2R ○ ;-N(OR ○ )R ○ ;-C(NH)NR ○ 2;-P(O)(OR ○ )R ○ ;-P(O)R ○ 2;-OP(O)R ○ 2;-OP(O)(OR ○ )2;-SiR ○ 3;-(C 1~4 straight or branched chain alkylene)ON(R ○ )2; or -(C 1~4 straight or branched chain alkylene)C(O)ON(R ○ )2, where each R ○ may be substituted as defined below and independently represent hydrogen, C 1~6 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, -CH2- (a 5- to 6-membered heteroaryl ring), or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, regardless of the above definitions, R ○two independent occurrences of together with the atom(s) between them form a 3- to 12-membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which can be substituted as defined below.

[0032] R ○ (R ○ Suitable monovalent substituents on the ring formed by two independent occurrences of (a ring formed by two independent occurrences of together with the atom between them) are independently halogen, -(CH2) 0~2 R ● ,-(Halo R ● ), -(CH2) 0~2 OH, -(CH2) 0~2 OR ● , -(CH2) 0~2 CH(OR ● )2;-O(HaloR ● ), -CN, -N3, -(CH2) 0~2 C(O)R ● , -(CH2) 0~2 C(O)OH, -(CH2) 0~2 C(O)OR ● , -(CH2) 0~2 SR ● , -(CH2) 0~2 SH, -(CH2) 0~2 NH2, -(CH2) 0~2 NHR ● , -(CH2) 0~2 NR ● 2, -NO2, -SiR ● 3. -OSiR ● 3. -C(O)SR ● , -(C 1~4 straight or branched chain alkylene)C(O)OR ● , or -SSR ● where each R ● is unsubstituted or, if preceded by "halo", is substituted with only one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. ○ Suitable divalent substituents on a saturated carbon atom of include ═O and ═S.

[0033] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include: ═O, ═S, ═NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2~3 O-, or -S(C(R * 2)) 2~3 S-. Here R * Each independent occurrence of may be hydrogen, C, which may be substituted as defined below. 1~6 and an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having an aliphatic or 0-4 heteroatom independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents attached to a vicinal substitutable carbon of an "optionally substituted" group include -O(CR * 2) 2~3 O-, where R * Each independent occurrence of may be hydrogen, C, which may be substituted as defined below. 1~6 It is selected from an aliphatic or unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0034] R * Suitable substituents on the aliphatic group include halogen, -R ● ,-(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR● , -NR ● 2, or -NO2, where each R ● is unsubstituted or, if preceded by "halo", is substituted with only one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0035] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2. -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CHC(O)R † , -S(O)2R † , -S(O)NR † 2. -C(S)NR † 2. -C(NH)NR † 2, or -N(R † )S(O)2R † where each R † are independently hydrogen, C which may be substituted as defined below 1~6 an aliphatic, unsubstituted -OPh, or an unsubstituted 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, regardless of the above definitions, R † two independent occurrences of together with the atom(s) between them form an unsubstituted 3- to 12-membered saturated, partially unsaturated, or aryl monocyclic or bicyclic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0036] R † Suitable substituents on the aliphatic group are independently halogen, -R ● ,-(Halo R ● ), -OH, -OR● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH2, -NHR ● , -NR ● 2, or -NO2, where each R ● is unsubstituted or, if preceded by "halo", is substituted with only one or more halogens, and independently, C 1~4 Aliphatic, -CH2Ph, -O(CH2) 0~1 Ph, or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0037] The term "isomer," as used herein, refers to compounds that have the same chemical formula but differ in structure or optical configuration. The term "stereoisomer," as used herein, refers to and includes isomeric molecules that have the same molecular formula but differ in the location of atoms and / or functional groups in space. All stereoisomers of the present compounds (e.g., those that may exist due to asymmetric carbons on various substituents), including enantiomeric and diastereomeric forms, are considered within the scope of the present disclosure. Thus, unless otherwise specified, single stereochemical isomers of the present compounds, as well as mixtures of enantiomeric, diastereomeric, and positional (or conformational) isomers, are within the scope of the present disclosure.

[0038] The term "tautomer," as used herein, refers to one of two or more structural isomers that exist in equilibrium and readily convert from one isomeric form to the other. Tautomers are understood to include valence tautomers and proton tautomers (also known as prototropic tautomers). Valence tautomers include interconversions via positional isomerism of some of the bonding electrons. Proton tautomers include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerism. Unless otherwise stated, all tautomers of the compounds of the present invention are within the scope of the present invention.

[0039] The term "isotopic substitution" as used herein refers to the replacement of an atom with its isotope. The term "isotope" as used herein refers to an atom that has the same atomic number as the atom that is predominant in nature, but has a mass number (number of neutrons) that is different from the mass number of the atom that is predominant in nature. A compound with isotopic substitution refers to a compound in which at least one atom contained therein is replaced with its isotope. Atoms that can be replaced with the isotope include, but are not limited to, hydrogen, carbon, and oxygen. Examples of isotopes of hydrogen atoms include: 2 H (also represented as D) and 3 H. Examples of carbon isotopes include: 13 C and 14 C. Examples of isotopes of the oxygen atom include: 18 O. Unless otherwise stated, all isotopic substitutions of the compounds of the invention are within the scope of the invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or as therapeutic agents according to the present invention. In certain embodiments, for example, the warhead moiety R of the provided compounds is W contains one or more deuterium atoms.

[0040] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and is commensurate with a reasonable benefit / risk ratio. Exemplary pharmaceutically acceptable salts are found, for example, in Berge, et al. (J. Pharm. Sci. 1977, 66(1), 1; and Gould, PL, Int. J. Pharmaceutics 1986, 33, 201-217; each of which is incorporated herein by reference in its entirety).

[0041] Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic acids, inorganic bases, organic acids, and organic bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid) or organic acids (e.g., acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid), or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, and the like. Examples of suitable salts include phosphate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and valerate.

[0042] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1~4Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate using counterions such as halides, hydroxides, carbonates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates.

[0043] Pharmaceutically acceptable salts are also intended to include hemisalts, where the ratio of compound to acid is 2:1, respectively. Exemplary hemisalts are salts derived from acids containing two carboxylic acid groups, such as malic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, glutaric acid, oxalic acid, adipic acid, and citric acid. Other exemplary hemisalts are salts derived from diprotic mineral acids, such as sulfuric acid. Exemplary preferred hemisalts include, but are not limited to, hemimaleate, hemifumarate, and hemisuccinate.

[0044] As used herein, the term "about" is used herein to mean approximately, roughly, in the region of, or in the region of. When the term "about" is used in connection with a numerical range, it modifies this range by extending the boundaries above and below the stated numerical values. In general, the term "about" is used herein to modify a numerical value above or below the stated value by a variance of 20 percent above or below (higher or lower).

[0045] As used herein, "effective amount," "sufficient amount," or "therapeutically effective amount" refers to an amount of a compound that is sufficient to produce beneficial or desired results, including clinical results. Thus, an effective amount may be sufficient, for example, to reduce or alleviate the severity and / or duration of a pain associated with FGFR2 signaling or one or more symptoms thereof, to prevent the progression of a condition or symptom associated with a pain associated with FGFR2 signaling, or to enhance or otherwise improve the prophylactic or therapeutic effect(s) of another treatment. An effective amount also encompasses the amount of a compound that avoids or substantially attenuates undesirable side effects.

[0046] As used herein, and as is well understood in the art, "treatment" refers to an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired clinical results may include, but are not limited to, alleviation or relief of one or more symptoms or conditions, whether detectable or undetectable, a reduction in the severity of the disease or affliction, a stabilized (i.e., non-worsening) state of the disease or affliction, prevention of the spread of the disease or affliction, a delay or slowing of the progression of the disease or affliction, a reduction or palliation of the disease or affliction state, and a remission (whether partial or total). "Treatment" may also mean prolonging survival compared to expected survival in the absence of treatment. In some embodiments, treatment may be administered after the onset of one or more symptoms. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual before the onset of symptoms (e.g., taking into account the history of the symptoms and / or taking into account genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, e.g., to prevent or delay the recurrence of the symptoms.

[0047] The phrase "in need thereof" refers to a need for symptomatic or asymptomatic relief from a condition associated with FGFR2 signaling activity or a condition that may otherwise be alleviated by the compounds and / or compositions of the present disclosure. 3. Description of Exemplary Embodiments

[0048] As noted above, in some embodiments, the present invention provides compounds of formula I-1: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula I-1: Cy A teeth, [ka] where [ka] is R 5 represents a bond to, and [ka] Cy 6 represents a bond to; R 5 -R 5A -L 5 -R 5B and; R 5A is R B where R 5A -L 5 -R 5B In addition, m examples of R 5C is replaced by; R 5B is hydrogen or R B where R 5B is n examples of R 5D is replaced by; Cy 6is phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Cy is 6 -L 6 -R W In addition, p examples of R 6 is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of R A or R B where R 6 is the number of q examples in R C is replaced by; or R 6 Two examples of R 6 One example of R L One example of this is R 6 One example of R WA One example of this is R 6 One example of R 7a together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; R 8 is H, -NR2, halogen, -OH, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 9is H, -NR2, halogen, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 10 is H or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; L 5 and L 6 each independently represents a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~6 Cycloalkylene, 3- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; 3~6 Each of cycloalkylene, 3- to 6-membered heterocycloalkylene, and 5- to 6-membered heteroarylene is selected from one example of R A or C 1~6 aliphatic and optionally substituted; R WA , R WB , and R WC are independently hydrogen, deuterium, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L together with the atoms therebetween to form a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of the w examples of R C is replaced by; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of R A or R B and u examples of R C is replaced by; or R 5C Two examples of R 5C One example of R 5D One example of, or R 5D two instances of R together with the atom between them form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is C is replaced by; R Aeach instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C and each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each of m, n, p, q, r, t, u, v, and w is independently 0, 1, 2, 3, or 4.

[0049] As generally defined above, Cy A teeth, [ka] where [ka] is R 5 represents a bond to, and [ka] Cy 6 In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, CyA teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] is.

[0050] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A teeth, [ka] In some embodiments, Cy A is selected from the groups depicted in the compounds of Table 1.

[0051] As generally defined above, Cy 6 is phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Cy is 6 -L 6 -R W In addition, p examples of R 6 is replaced by .

[0052] In some embodiments, Cy 6 is phenylene; a divalent saturated or partially unsaturated 3- to 7-membered monocyclic carbocyclic ring; a divalent saturated or partially unsaturated 8- to 14-membered bicyclic carbocyclic ring; a divalent saturated or partially unsaturated 3- to 7-membered monocyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a divalent saturated or partially unsaturated 8- to 14-membered bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 5- to 6-membered monocyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 9- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 is replaced by .

[0053] In some embodiments, Cy 6is a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a divalent saturated or partially unsaturated 3- to 7-membered monocyclic carbocyclic ring or a divalent saturated or partially unsaturated 8- to 14-membered bicyclic carbocyclic ring; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a divalent saturated or partially unsaturated 3- to 7-membered monocyclic carbocyclic ring; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a divalent saturated or partially unsaturated 8- to 14-membered bicyclic carbocyclic ring; 6 -L 6 -R W In addition, p examples of R 6 is replaced by .

[0054] In some embodiments, Cy 6 is a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a divalent saturated or partially unsaturated 3- to 7-membered monocyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a divalent saturated or partially unsaturated 8- to 14-membered bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Cy 6-L 6 -R W In addition, p examples of R 6 is replaced by .

[0055] In some embodiments, Cy 6 is a divalent saturated or partially unsaturated 3- to 7-membered monocyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a divalent saturated or partially unsaturated 5- to 6-membered monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a divalent pyrrolidine or dihydropyrrolidine ring; 6 -L 6 -R W In addition, p examples of R 6 is replaced by .

[0056] In some embodiments, Cy 6 is a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a 5- to 6-membered monocyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 9- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein Cy is 6 -L6 -R W In addition, p examples of R 6 is replaced by .

[0057] In some embodiments, Cy 6 is a 5- to 6-membered monocyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a 5- to 6-membered monocyclic heteroarylene having 1 to 2 nitrogen atoms; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a 5-membered monocyclic heteroarylene having 1 to 2 nitrogen atoms; 6 -L 6 -R W In addition, p examples of R 6 is replaced by .

[0058] In some embodiments, Cy 6 is a 9- to 10-membered bicyclic heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 is a 9- to 10-membered bicyclic heteroarylene having 1 to 3 nitrogen atoms; 6 -L 6 -R W In addition, p examples of R 6 is replaced by .

[0059] In some embodiments, Cy 6is selected from the groups depicted in the compounds of Table 1.

[0060] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] [ka] and Here, L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] and Here, L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] and Here, L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] [ka] and Here, L 6 , R 6 , R W , and p are as defined in the embodiments and classes and subclasses herein.

[0061] As generally defined above, R 6 Each instance of A or R B where R 6 is the number of q examples in R C or R 6 Two examples of R 6 One example of R L One example of this is R 6 One example of R WA One example of this is R 6 One example of R 7a together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by .

[0062] In some embodiments, R 6 Two examples of R 6 One example of R L One example of this is R 6 One example of R WA One example of this is R 6 One example of R 7a together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by .

[0063] In some embodiments, R 6 One example of R WA together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C In some embodiments, R 6 One example of R 7a together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by .

[0064] In some embodiments, R 6 One example of R 7a together with the atoms therebetween to form a 4- to 8-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C In some embodiments, R 6 One example of R 7a together with the atoms between them to form a 4- to 8-membered partially unsaturated ring having one nitrogen atom; where the ring is not substituted with halogen, -CN, -O-(C 1~4 alkyl), and -(C 1~4 alkyl); wherein each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 fluoro. In some embodiments, R 6 One example of R 7a One example is when R is taken together with the atoms between them to form a 4- to 8-membered partially unsaturated ring. 6 One example of R 7aAn example of is when taken together with the atoms between them to form a 4- to 8-membered partially unsaturated ring having one nitrogen atom.

[0065] In some embodiments, each R 6 is selected from the groups depicted in the compounds of Table 1.

[0066] As generally defined above, R 8 is H, -NR2, halogen, -OH, or C optionally substituted with 1 to 3 halogens 1~6 In some embodiments, R 8 is H. In some embodiments, R 8 is -NR2. In some embodiments, R 8 is halogen. In some embodiments, R 8 is —OH. In some embodiments, R 8 is C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic.

[0067] In some embodiments, R 8 is -NH2. In some embodiments, R 8 is C 1~4 In some embodiments, R 8 is methyl. In some embodiments, R 8 is —NH or methyl. In some embodiments, R 8 is selected from the groups depicted in the compounds of Table 1.

[0068] As generally defined above, R 9 is H, -NR2, halogen, or C optionally substituted with 1 to 3 halogens 1~6 In some embodiments, R 9 is H. In some embodiments, R 9 is -NR2. In some embodiments, R 9 is -NH2. In some embodiments, R9 is halogen. In some embodiments, R 9 is C optionally substituted with 1 to 3 halogens 1~6 In some embodiments, R 9 is C 1~4 In some embodiments, R 9 is selected from the groups depicted in the compounds of Table 1.

[0069] As generally defined above, R 10 is H or C optionally substituted with 1 to 3 halogens 1~6 In some embodiments, R 10 is H. In some embodiments, R 10 is C optionally substituted with 1 to 3 halogens 1~6 In some embodiments, R 10 is C 1~4 In some embodiments, R 10 is methyl. In some embodiments, R 10 is H or methyl. In some embodiments, R 10 is selected from the groups depicted in the compounds of Table 1.

[0070] As generally defined above, L 6 is a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~6 Cycloalkylene, 3- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(RL )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; 3~6 Each of cycloalkylene, 3- to 6-membered heterocycloalkylene, and 5- to 6-membered heteroarylene is selected from one example of R A or C 1~6 Aliphatic and optionally substituted.

[0071] In some embodiments, L 6 is C 3~6 cycloalkylene, 3- to 6-membered heterocycloalkylene, or 5- to 6-membered heteroarylene, each of which is selected from one example of R A or C 1~6 In some embodiments, L 6 is C 3~6 It is cycloalkylene, 3- to 6-membered heterocycloalkylene, or 5- to 6-membered heteroarylene.

[0072] In some embodiments, L 6 is selected from the groups depicted in the compounds of Table 1.

[0073] As generally defined above, R 5C Each example and R 5D are independent, R A or R B and u examples of R C or R 5C Two examples of R 5C One example of R 5D One example of, or R 5D two instances of R together with the atom between them form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is C is replaced by .

[0074] In some embodiments, R5C two instances of R together with the atom between them form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is C is replaced by .

[0075] In some embodiments, R 5C One example of R 5D together with the atoms therebetween to form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is a ring selected from the v examples of R C In some embodiments, R 5C One example of R 5D One example of R, together with the atoms between them, is C Forms a 3- to 7-membered saturated or partially unsaturated carbocyclic ring substituted with

[0076] In some embodiments, R 5D two instances of R together with the atom between them form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is C In some embodiments, R 5D Two instances of v, together with the atoms between them, form R C Forms a 3- to 7-membered saturated or partially unsaturated carbocyclic ring substituted with

[0077] In some embodiments, R 5C Each example and R 5D is selected from the groups depicted in the compounds of Table 1.

[0078] As generally defined above, v is 0, 1, 2, 3, or 4. In some embodiments, v is 0. In some embodiments, v is 1. In some embodiments, v is 2. In some embodiments, v is 3. In some embodiments, v is 4. In some embodiments, v is 0 or 1. In some embodiments, v is 0, 1, or 2. In some embodiments, v is 0, 1, 2, or 3. In some embodiments, v is 1 or 2. In some embodiments, v is 1, 2, or 3. In some embodiments, v is 1, 2, 3, or 4. In some embodiments, v is 2 or 3. In some embodiments, v is 2, 3, or 4. In some embodiments, v is 3 or 4. In some embodiments, v is selected from the values ​​set forth in the compounds of Table 1.

[0079] As generally defined above, w is 0, 1, 2, 3, or 4. In some embodiments, w is 0. In some embodiments, w is 1. In some embodiments, w is 2. In some embodiments, w is 3. In some embodiments, w is 4. In some embodiments, w is 0 or 1. In some embodiments, w is 0, 1, or 2. In some embodiments, w is 0, 1, 2, or 3. In some embodiments, w is 1 or 2. In some embodiments, w is 1, 2, or 3. In some embodiments, w is 1, 2, 3, or 4. In some embodiments, w is 2 or 3. In some embodiments, w is 2, 3, or 4. In some embodiments, w is 3 or 4. In some embodiments, w is selected from the values ​​shown in the compounds of Table 1.

[0080] In some embodiments, the present invention provides compounds of Formula I-1, wherein each of the variables, both alone and in combination, is as defined below in the description of Formula I or Formula I-2 and as described in embodiments herein.

[0081] As noted above, in some embodiments, the present invention provides compounds of formula I-2: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula I-2: R 5 -R 5A -L 5 -R 5B and; R 5A is R B where R 5A -L 5 -R 5B In addition, m examples of R 5C is replaced by; R 5B is hydrogen or R B where R 5B is n examples of R 5D is replaced by; Cy 6 is phenylene or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 -L 6 -R W In addition, p examples of R 6 is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of A or R B where R 6 is the number of q examples in R Cis replaced by; or R 6 Two examples of R 6 One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; L 5 and L 6 each independently represents a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; R WA , R WB , and R WC are independently hydrogen, deuterium, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is a ring formed by combining the atoms between them to form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of A or R B and u examples of R C is replaced by; R A each instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C and each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0082] As generally defined above, R WA , R WB , and R WC are independently hydrogen, deuterium, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is: which, together with the atoms therebetween, forms a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0083] In some embodiments, R WA , R WB , and R WC is independently hydrogen, deuterium, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, or —C(O)N(R)OR. In some embodiments, R WA , R WB , and R WC each independently represents hydrogen, deuterium, or an optionally substituted C1~6 In some embodiments, R WA , R WB , and R WC each independently represents hydrogen, deuterium, -C 1~4 Alkyl, -(C 1~4 alkyl)-O-(C 1~4 alkyl), or -(C 1~4 alkyl)-N(C 1~4 alkyl)2; where each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 fluoro. In some embodiments, R WA , R WB , and R WC each independently represents -C optionally substituted with hydrogen, deuterium, or 1, 2, or 3 fluoro; 1~4 In some embodiments, R WA , R WB , and R WC each independently represents hydrogen, deuterium, or -C 1~4 In some embodiments, R WA , R WB , and R WC Each of R is independently hydrogen, deuterium, or —CH. WA , R WB , and R WC Each of R is independently hydrogen or deuterium. WA , R WB , and R WC Each of is a deuterium.

[0084] In some embodiments, the present invention provides compounds of Formula I-2, wherein each of the variables, both alone and in combination, is as defined in the description of Formula I below and as described in embodiments herein.

[0085] As noted above, in some embodiments, the present invention provides a compound of formula I: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula I: R 5 -R 5A -L 5 -R 5B and; R 5A is R B where R 5A -L 5 -R 5B In addition, m examples of R 5C is replaced by; R 5B is hydrogen or R B where R 5B is n examples of R 5D is replaced by; Cy 6 is phenylene or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 -L 6 -R W In addition, p examples of R 6 is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of A or R B where R 6 is the number of q examples in R C is replaced by; or R 6 Two examples of R 6 One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; L 5 and L 6 each independently represents a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; R WA , R WB , and R WC are independently hydrogen, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R LAn example of is a ring formed by combining the atoms between them to form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of A or R B and u examples of R C is replaced by; R A each instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R Cand each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0086] As generally defined above, R 5A is R B where R 5A -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R 5A -L5 -R 5B In addition, m examples of R 5C Divalent C substituted with 1~6 In some embodiments, R 5A -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R 5A is a 5- to 6-membered monocyclic heteroarylene ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R 5A is an 8- to 10-membered bicyclic heteroarylene ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R 5A -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R is a divalent 3- to 7-membered saturated or partially unsaturated carbocyclic ring substituted with 5A is a divalent 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R 5A is a divalent 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; -L 5 -R 5B In addition, m examples of R 5C In some embodiments, R 5A is selected from the groups depicted in the compounds of Table 1.

[0087] As generally defined above, L 5 is a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L In some embodiments, L is optionally replaced by -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-. 5 is a covalent bond. In some embodiments, L 5 is C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate.

[0088] In some embodiments, L 5is C 1~2 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L In some embodiments, L is optionally replaced by -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-. 5 is C 1~2 wherein one or two methylene units of the chain are independently —O—, —C(O)—, —C(O)NH—, or —C(O)N(R L )- has been substituted as needed.

[0089] In some embodiments, L 5 is -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L In some embodiments, L 5 is —O—. In some embodiments, L 5 is —C(O)—. In some embodiments, L 5 is —C(O)NH—. In some embodiments, L 5 is -C(O)N(R L In some embodiments, L 5 is selected from the groups depicted in the compounds of Table 1.

[0090] As generally defined above, R 5B is hydrogen or RB where R 5B is n examples of R 5D In some embodiments, R 5B is hydrogen. In some embodiments, R 5B is n examples of R 5D R replaced by B In some embodiments, R 5B is n examples of R 5D C replaced with 1~6 In some embodiments, R 5B is n examples of R 5D In some embodiments, R 5B is a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D In some embodiments, R 5B is an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D In some embodiments, R 5B is n examples of R 5D In some embodiments, R is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring substituted with 5B is a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D In some embodiments, R 5B is a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D is replaced by .

[0091] In some embodiments, R 5Bis a 4- to 6-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D In some embodiments, R 5B is a 5-membered monocyclic heteroaryl ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D In some embodiments, R 5B is a 6-membered monocyclic heteroaryl ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; n instances of R 5D In some embodiments, R 5B is selected from the groups depicted in the compounds of Table 1.

[0092] As generally defined above, R 5C Each instance of R A or R B and u examples of R C In some embodiments, R 5C Each example in R A In some embodiments, R 5C is independently selected from halogen, —CN, —OR, —S(O)NR, —C(O)R, —C(O)OR, —C(O)NR, —OC(O)R, and —N(R)C(O)R. In some embodiments, R 5C Each instance of is independently selected from halogen, —CN, —OR, and —C(O)NR. In some embodiments, R 5C Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 alkyl)2; wherein each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 halogens. In some embodiments, R 5C Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C1~4 alkyl)2.

[0093] In some embodiments, R 5C Each example in R B where R 5C Let's look at the examples of R C In some embodiments, R 5C Each example in R B where R 5C Here is an example of R C In some embodiments, R 5C Each example of C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from u instances of R C are substituted as necessary by

[0094] In some embodiments, R 5C Each example of C 1~6 aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic ring; and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from u instances of R C In some embodiments, R 5C Each instance of is independently one instance of R C C replaced as needed by 1~4 and 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with one, two, or three halogens. In some embodiments, R 5C Each example is independently -OH, -O-(C1~4 alkyl), or -N(C 1~4 C optionally substituted with one example of alkyl)2 1~4 and a 3- to 5-membered saturated carbocyclic ring; and a 3- to 5-membered saturated monocyclic heterocyclic ring containing one oxygen atom; each of which is optionally substituted with one, two, or three fluoro or chloro.

[0095] In some embodiments, R 5C Each instance of is independently selected from halogen, -CN, -OR, -C(O)NR, and each of u instances of R C The following groups optionally substituted with: C 1~6 aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic ring; and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5C Each instance of is independently selected from halogen, —CN, and the following groups, each of which is optionally substituted with 1, 2, or 3 halogens: —O—(C 1~4 alkyl), -C(O)N(C 1~4 alkyl)2, one example of R C C replaced as needed by 1~4 aliphatic; 3- to 5-membered saturated carbocyclic ring; and 3- to 5-membered saturated monocyclic heterocyclic ring having one heteroatom independently selected from nitrogen, oxygen, and sulfur. 5C Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), -C(O)N(C 1~4 alkyl)2, and the following groups, each optionally substituted with 1, 2, or 3 fluoro or chloro: -OH, -O-(C 1~4 alkyl), or -N(C 1~4 C optionally substituted with one example of alkyl)2 1~4alkyl; a 3- to 5-membered saturated carbocyclic ring; and a 3- to 5-membered saturated monocyclic heterocyclic ring containing one oxygen atom. 5C is selected from the groups depicted in the compounds of Table 1.

[0096] As generally defined above, R 5D Each instance of R A or R B and u examples of R C In some embodiments, R 5D Each example in R A In some embodiments, R 5D is independently selected from halogen, —CN, —OR, —S(O)NR, —C(O)R, —C(O)OR, —C(O)NR, —OC(O)R, and —N(R)C(O)R. In some embodiments, R 5D Each instance of is independently selected from halogen, —CN, —OR, and —C(O)NR. In some embodiments, R 5D Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 alkyl)2; wherein each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 halogens. In some embodiments, R 5D Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 alkyl)2.

[0097] In some embodiments, R 5D Each example in R B where R 5D Let's look at the examples of R C In some embodiments, R 5D Each example in R B where R 5D Here is an example of R CIn some embodiments, R 5D Each example of C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from u instances of R C are substituted as necessary by

[0098] In some embodiments, R 5D Each example of C 1~6 aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic ring; and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from u instances of R C In some embodiments, R 5D Each instance of is independently one instance of R C C replaced as needed by 1~4 and 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with one, two, or three halogens. In some embodiments, R 5D Each example is independently -OH, -O-(C 1~4 alkyl), or -N(C 1~4 C optionally substituted with one example of alkyl)2 1~4 and a 3- to 5-membered saturated carbocyclic ring; and a 3- to 5-membered saturated monocyclic heterocyclic ring containing one oxygen atom; each of which is optionally substituted with one, two, or three fluoro or chloro.

[0099] In some embodiments, R 5DEach instance of is independently selected from halogen, -CN, -OR, -C(O)NR, and each of u instances of R C The following groups optionally substituted with: C 1~6 aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic ring; and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 5D Each instance of is independently selected from halogen, —CN, and the following groups, each of which is optionally substituted with 1, 2, or 3 halogens: —O—(C 1~4 alkyl), -C(O)N(C 1~4 alkyl)2, one example of R C C replaced as needed by 1~4 aliphatic; 3- to 5-membered saturated carbocyclic ring; and 3- to 5-membered saturated monocyclic heterocyclic ring having one heteroatom independently selected from nitrogen, oxygen, and sulfur. 5D Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), -C(O)N(C 1~4 alkyl)2, and the following groups, each optionally substituted with 1, 2, or 3 fluoro or chloro: -OH, -O-(C 1~4 alkyl), or -N(C 1~4 C optionally substituted with one example of alkyl)2 1~4 alkyl; a 3- to 5-membered saturated carbocyclic ring; and a 3- to 5-membered saturated monocyclic heterocyclic ring containing one oxygen atom. 5D is selected from the groups depicted in the compounds of Table 1.

[0100] In some embodiments, the present invention provides compounds of formula I, as generally defined above, wherein R 5 -R 5A -L 5 -R 5B In some embodiments, R 5 (i.e., -R5A -L 5 -R 5B (combined with): [ka] where L 5 , R 5B , R 5C , and m are as defined in the embodiments and classes and subclasses herein.

[0101] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (combined with): [ka] where R 5B , R 5C , and m are as defined in the embodiments and classes and subclasses herein.

[0102] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (combined with): [ka] where R 5B , R 5C , and m are as defined in the embodiments and classes and subclasses herein.

[0103] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (combined with): [ka] where R 5B , R 5C , and m are as defined in the embodiments and classes and subclasses herein.

[0104] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (combined with): [ka] where R 5B , R 5C , and m are as defined in the embodiments and classes and subclasses herein.

[0105] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (combined with): [ka] where R 5B and R 5C Each of the is as defined in the embodiments and classes and subclasses herein.

[0106] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B (combined with): [ka] where R 5B and R 5C Each of the is as defined in the embodiments and classes and subclasses herein.

[0107] In some embodiments, R 5 (i.e., -R 5A -L 5 -R 5B together) are selected from the groups depicted in the compounds of Table 1.

[0108] As generally defined above, Cy 6 is phenylene or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 -L 6 -R W In addition to p examples of R 6 In some embodiments, Cy is phenylene substituted with 6 is a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 -L 6 -R W In addition, p examples of R 6 In some embodiments, Cy is substituted with 6 has 1 to 2 nitrogen atoms, -L 6 -R W In addition to p examples of R 6 In some embodiments, Cy is a 6-membered heteroarylene substituted with 6 has one nitrogen atom and -L 6 -R W In addition to p examples of R 6 In some embodiments, Cy is a 6-membered heteroarylene substituted with 6 has two nitrogen atoms and -L 6 -R W In addition to p examples of R 6 In some embodiments, Cy is a 6-membered heteroarylene substituted with 6 has two nitrogen atoms and -L 6 -R WIn some embodiments, Cy is a 6-membered heteroarylene substituted only with 6 has 1 to 2 nitrogen atoms, -L 6 -R W In addition to p examples of R 6 and 6-membered heteroarylene substituted with L 6 is a covalent bond, and -R W is -CN or [ka] In some embodiments, Cy 6 is selected from the groups depicted in the compounds of Table 1.

[0109] As generally defined above, R 6 Each instance of R A or R B where R 6 is the number of q examples in R C or R 6 Two examples of R 6 One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C In some embodiments, R 6 Each instance of R A or R B where R 6 is the number of q examples in R C is replaced by

[0110] In some embodiments, R 6 Two examples of R 6 One example of R Ltogether with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C In some embodiments, R 6 two instances of R, taken together with the atom between them, form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is C is replaced by .

[0111] In some embodiments, R 6 One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C In some embodiments, R 6 One example of R L together with the atoms between them to form a 4- to 7-membered partially unsaturated ring having one nitrogen atom; where the ring is not substituted with halogen, -CN, -O-(C 1~4 alkyl), and -(C 1~4 alkyl); wherein each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 fluoro. In some embodiments, R 6 One example of R L An example of is when taken together with the atoms between them to form a 4- to 7-membered partially unsaturated ring having one nitrogen atom.

[0112] In some embodiments, R 6 Each example in R A In some embodiments, R 6is independently selected from halogen, —CN, —OR, —S(O)NR, —C(O)R, —C(O)OR, —C(O)NR, —OC(O)R, and —N(R)C(O)R. In some embodiments, R 6 Each instance of is independently selected from halogen, —CN, —OR, and —C(O)NR. In some embodiments, R 6 Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 alkyl)2; wherein each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 halogens. In some embodiments, R 6 Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), and -C(O)N(C 1~4 alkyl)2.

[0113] In some embodiments, R 6 Each example in R B where R 6 is the number of q examples in R C In some embodiments, R 6 Each example in R B where R 6 Here is an example of R C In some embodiments, R 6 Each example of C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from q instances of R C are substituted as necessary by

[0114] In some embodiments, R 6 Each example of C1~6 aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic ring; and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from q instances of R C In some embodiments, R 6 Each instance of is independently one instance of R C C replaced as needed by 1~4 and 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic heterocyclic rings having one heteroatom independently selected from nitrogen, oxygen, and sulfur; each of which is optionally substituted with one, two, or three halogens. In some embodiments, R 6 Each example is independently -OH, -O-(C 1~4 alkyl), or -N(C 1~4 C optionally substituted with one example of alkyl)2 1~4 and 3- to 5-membered saturated carbocyclic rings; and 3- to 5-membered saturated monocyclic heterocyclic rings containing one oxygen atom; each of which is optionally substituted with one, two, or three fluoro or chloro.

[0115] In some embodiments, R 6 each instance of is independently selected from halogen, —CN, —OR, —C(O)NR, and each q instances of R C The following groups optionally substituted with: C 1~6 aliphatic; 3- to 7-membered saturated or partially unsaturated carbocyclic ring; and 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R 6 Each instance of is independently selected from halogen, —CN, and the following groups, each of which is optionally substituted with 1, 2, or 3 halogens: —O—(C 1~4 alkyl), -C(O)N(C 1~4 alkyl)2, one example of RC C replaced as needed by 1~4 aliphatic; 3- to 5-membered saturated carbocyclic ring; and 3- to 5-membered saturated monocyclic heterocyclic ring having one heteroatom independently selected from nitrogen, oxygen, and sulfur. 6 Each example is independently a halogen, -CN, -O-(C 1~4 alkyl), -C(O)N(C 1~4 alkyl)2, and the following groups, each optionally substituted with 1, 2, or 3 fluoro or chloro: -OH, -O-(C 1~4 alkyl), or -N(C 1~4 C optionally substituted with one example of alkyl)2 1~4 alkyl; a 3- to 5-membered saturated carbocyclic ring; and a 3- to 5-membered saturated monocyclic heterocyclic ring containing one oxygen atom. 6 is selected from the groups depicted in the compounds of Table 1.

[0116] As generally defined above, L 6 is a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L In some embodiments, L is optionally replaced by -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-. 6 is a covalent bond. In some embodiments, L6 is C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate.

[0117] In some embodiments, L 6 is C 1~2 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L In some embodiments, L is optionally replaced by -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-. 6 is C 1~2 wherein one methylene unit of the chain is —NH— or —N(RL )- has been substituted as needed.

[0118] In some embodiments, L 6 is -NH- or -N(R L In some embodiments, L 6 In some embodiments, L 6 -N(R L In some embodiments, L 6 is —NH— or —N(CH)—. In some embodiments, L 6 is —N(CH)—. In some embodiments, L 6 is selected from the groups depicted in the compounds of Table 1.

[0119] As generally defined above, R W is a halogen, -CN, [ka] In some embodiments, R W is a halogen, -CN, [ka] is.

[0120] In some embodiments, R W is halogen. In some embodiments, R W is -CN. In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] is.

[0121] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] is.

[0122] In some embodiments, R W is -CN, [ka] In some embodiments, R W teeth, [ka] In some embodiments, R W teeth, [ka] is.

[0123] In some embodiments, R W teeth, [ka] and R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is: which, together with the atoms therebetween, forms a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0124] In some embodiments, R W teeth, [ka] and R WA and R WB , or R WB and R WCtogether with the atoms therebetween to form a 4- to 7-membered partially unsaturated ring having 0 to 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. W teeth, [ka] and R WA and R L In some embodiments, R is a 4- to 7-membered saturated or partially unsaturated ring having 0 to 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. W teeth, [ka] and R WC and R L One example of R is, taken together with the atoms between them, forming a 4- to 7-membered partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. W is selected from the groups depicted in the compounds of Table 1.

[0125] While not wishing to be bound by any particular theory, R W is a warhead group and is believed to be particularly suitable for covalent attachment to sulfhydryl side chain moieties of protein kinases, e.g., Cys491 of FGFR2. Thus, in some embodiments, R W is characterized by its ability to covalently bind to a cysteine ​​residue, thereby irreversibly inhibiting a protein kinase. In some embodiments, the protein kinase is FGFR. In certain embodiments, the protein kinase is FGFR2. In certain embodiments, the protein kinase is FGFR2 and the cysteine ​​residue is Cys491.

[0126] As generally defined above, RWA , R WB , and R WC are independently hydrogen, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is: which, together with the atoms therebetween, forms a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0127] In some embodiments, R WA , R WB , and R WC are independently hydrogen, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 In some embodiments, R is selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R LAn example of is: which, together with the atoms therebetween, forms a 4- to 7-membered saturated or partially unsaturated ring having 0 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0128] In some embodiments, R WA , R WB , and R WC Each of is independently hydrogen, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, or —C(O)N(R)OR. In some embodiments, R WA , R WB , and R WC Each of the 1~6 An optionally substituted group selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[0129] In some embodiments, R WA , R WB , and R WC each independently represents hydrogen or an optionally substituted C 1~6 In some embodiments, R WA , R WB , and R WC each independently represents hydrogen or an optionally substituted C 1~6 In some embodiments, R WA , R WB , and R WC each independently represents hydrogen, -C 1~4 Alkyl, -(C 1~4 alkyl)-O-(C 1~4 alkyl), or -(C 1~4 alkyl)-N(C 1~4 alkyl)2; where each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 fluoro. In some embodiments, RWA , R WB , and R WC each independently is hydrogen or —C optionally substituted with 1, 2, or 3 fluoro 1~4 In some embodiments, R WA , R WB , and R WC each independently represents hydrogen or -C 1~4 In some embodiments, R WA , R WB , and R WC Each of is independently hydrogen or —CH 3 .

[0130] In some embodiments, R WA and R WB , or R WB and R WC together with the atoms therebetween to form a 4- to 7-membered partially unsaturated ring having 0 to 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. WA and R WB , or R WB and R WC together with the atoms between them form a 4- to 7-membered partially unsaturated carbocyclic ring. WA and R L In some embodiments, R is a 4- to 7-membered saturated or partially unsaturated ring having 0 to 1 heteroatom independently selected from nitrogen, oxygen, and sulfur. WC and R L One example of R is, taken together with the atoms between them, forming a 4- to 7-membered partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. WC and R L One example of R is, taken together with the atoms between them, forming a 5- to 6-membered partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. WA , RWB , and R WC Each of is selected from the groups depicted in the compounds of Table 1.

[0131] As generally defined above, R WD is halogen or —OS(O)R. In some embodiments, R WD is halogen. In some embodiments, R WD In some embodiments, R is chloro or bromo. WD is chloro. In some embodiments, R WD is —OS(O)R. In some embodiments, R WD is -OS(O)2- (optionally substituted C 1~3 In some embodiments, R WD is —OS(O)2CH3 or —OS(O)2CF3. In some embodiments, R WD is —OS(O)— (optionally substituted phenyl). In some embodiments, R WD is selected from the groups depicted in the compounds of Table 1.

[0132] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6, R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 and R W Each of the is as defined in the embodiments and classes and subclasses herein.

[0133] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W , and p are as defined in the embodiments and classes and subclasses herein.

[0134] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 and R W Each of the is as defined in the embodiments and classes and subclasses herein.

[0135] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 and R W Each of the is as defined in the embodiments and classes and subclasses herein.

[0136] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W Each of -Cy and p is as defined in the embodiments and classes and subclasses herein. 6 -L 6 -R W together with: [ka] where L 6 , R 6 , R W , and p are as defined in the embodiments and classes and subclasses herein.

[0137] In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L 6 -R W together with: [ka] where L 6 , R 6 , and R W each as defined in the embodiments and classes and subclasses herein. In some embodiments, -Cy 6 -L6 -R W together with: [ka] where L 6 and R W Each of the is as defined in the embodiments and classes and subclasses herein.

[0138] In some embodiments, -Cy 6 -L 6 -R W is selected from the groups depicted in the compounds of Table 1.

[0139] As generally defined above, R 7 is H or R B where R 7 Let's look at t examples of R 7A In some embodiments, R 7 is H. In some embodiments, R 7 is R B where R 7 Let's look at t examples of R 7A In some embodiments, R 7 is C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; or a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from t instances of R 7A In some embodiments, R 7 is C 1~6 aliphatic; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; or a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of which is selected from t instances of R 7Ais replaced by .

[0140] In some embodiments, R 7 is C 1~6 alkyl; a 3- to 7-membered saturated carbocyclic ring; or a 3- to 7-membered saturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen and oxygen; each of which may be selected from 0 to 1 instances of R 7A and 0 to 3 halogens. In some embodiments, R 7 is 0 to 1 example R 7A and C substituted with 0 to 3 halogens 1~6 In some embodiments, R 7 -C 1~4 Alkyl, -(C 1~4 alkyl)-OH, -(C 1~4 alkyl)-O-(C 1~4 alkyl), or -(C 1~4 alkyl)-N(C 1~4 alkyl)2; where each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 fluoro. In some embodiments, R 7 -C 1~4 In some embodiments, R is alkyl and is optionally substituted with 1, 2, or 3 fluoro. 7 is —CH3. In some embodiments, R 7 is 0 to 1 example R B and C substituted with 0 to 3 halogens 1~6 It is alkyl.

[0141] In some embodiments, R 7 is 0 to 1 example R 7A and a 3- to 7-membered saturated carbocyclic ring substituted with 0-3 halogens. 7 is a 3- to 7-membered saturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen and oxygen; which is represented by 0 to 1 instances of R 7Aand 0 to 3 halogens. In some embodiments, R 7 is a 5- to 6-membered saturated monocyclic heterocyclic ring having one oxygen atom; which is represented by 0 to 1 instances of R 7A and 0 to 3 halogens. In some embodiments, R 7 is a 5- to 6-membered saturated monocyclic heterocyclic ring having one oxygen atom; which is selected from the group consisting of 0 to 3 halogens, and -C 1~4 Alkyl, -OH, -O-(C 1~4 alkyl), or N(C 1~4 alkyl)2; wherein each C 1~4 The alkyl is optionally substituted with 1, 2, or 3 fluoro. In some embodiments, R 7 is a 5- to 6-membered saturated monocyclic heterocyclic ring containing one oxygen atom. 7 is selected from the groups depicted in the compounds of Table 1.

[0142] As generally defined above, m is 0, 1, 2, 3, or 4. In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 0 or 1. In some embodiments, m is 0, 1, or 2. In some embodiments, m is 0, 1, 2, or 3. In some embodiments, m is 1 or 2. In some embodiments, m is 1, 2, or 3. In some embodiments, m is 1, 2, 3, or 4. In some embodiments, m is 2 or 3. In some embodiments, m is 2, 3, or 4. In some embodiments, m is 3 or 4. In some embodiments, m is selected from the values ​​set forth in the compounds of Table 1.

[0143] As generally defined above, n is 0, 1, 2, 3, or 4. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 0 or 1. In some embodiments, n is 0, 1, or 2. In some embodiments, n is 0, 1, 2, or 3. In some embodiments, n is 1 or 2. In some embodiments, n is 1, 2, or 3. In some embodiments, n is 1, 2, 3, or 4. In some embodiments, n is 2 or 3. In some embodiments, n is 2, 3, or 4. In some embodiments, n is 3 or 4. In some embodiments, n is selected from the values ​​set forth in the compounds of Table 1.

[0144] As generally defined above, p is 0, 1, 2, 3, or 4. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 0 or 1. In some embodiments, p is 0, 1, or 2. In some embodiments, p is 0, 1, 2, or 3. In some embodiments, p is 1 or 2. In some embodiments, p is 1, 2, or 3. In some embodiments, p is 1, 2, 3, or 4. In some embodiments, p is 2 or 3. In some embodiments, p is 2, 3, or 4. In some embodiments, p is 3 or 4. In some embodiments, p is selected from the values ​​set forth in the compounds of Table 1.

[0145] As generally defined above, q is 0, 1, 2, 3, or 4. In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 0 or 1. In some embodiments, q is 0, 1, or 2. In some embodiments, q is 0, 1, 2, or 3. In some embodiments, q is 1 or 2. In some embodiments, q is 1, 2, or 3. In some embodiments, q is 1, 2, 3, or 4. In some embodiments, q is 2 or 3. In some embodiments, q is 2, 3, or 4. In some embodiments, q is 3 or 4. In some embodiments, q is selected from the values ​​set forth in the compounds of Table 1.

[0146] As generally defined above, r is 0, 1, 2, 3, or 4. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 0 or 1. In some embodiments, r is 0, 1, or 2. In some embodiments, r is 0, 1, 2, or 3. In some embodiments, r is 1 or 2. In some embodiments, r is 1, 2, or 3. In some embodiments, r is 1, 2, 3, or 4. In some embodiments, r is 2 or 3. In some embodiments, r is 2, 3, or 4. In some embodiments, r is 3 or 4. In some embodiments, r is selected from the values ​​shown in the compounds of Table 1.

[0147] As generally defined above, t is 0, 1, 2, 3, or 4. In some embodiments, t is 0. In some embodiments, t is 1. In some embodiments, t is 2. In some embodiments, t is 3. In some embodiments, t is 4. In some embodiments, t is 0 or 1. In some embodiments, t is 0, 1, or 2. In some embodiments, t is 0, 1, 2, or 3. In some embodiments, t is 1 or 2. In some embodiments, t is 1, 2, or 3. In some embodiments, t is 1, 2, 3, or 4. In some embodiments, t is 2 or 3. In some embodiments, t is 2, 3, or 4. In some embodiments, t is 3 or 4. In some embodiments, t is selected from the values ​​set forth in the compounds of Table 1.

[0148] As generally defined above, u is 0, 1, 2, 3, or 4. In some embodiments, u is 0. In some embodiments, u is 1. In some embodiments, u is 2. In some embodiments, u is 3. In some embodiments, u is 4. In some embodiments, u is 0 or 1. In some embodiments, u is 0, 1, or 2. In some embodiments, u is 0, 1, 2, or 3. In some embodiments, u is 1 or 2. In some embodiments, u is 1, 2, or 3. In some embodiments, u is 1, 2, 3, or 4. In some embodiments, u is 2 or 3. In some embodiments, u is 2, 3, or 4. In some embodiments, u is 3 or 4. In some embodiments, u is selected from the values ​​set forth in the compounds of Table 1.

[0149] In some embodiments, the present invention includes a pyrrolopyrimidine, pyrrolotriazine, pyrazolopyrazine, pyrrolopyridine, furopyrimidine, thienopyrimidine, or pyrrolopyridazinone, thereby having formula Ia, Ib, Ic, Id, Ie, If, Ig, or Ih: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula Ia, Ib, Ic, Id, Ie, If, Ig, and Ih, Cy 6 , L 6 , R W , R 5 , R 7 , R 8 , R 9 , and R 10 Each of the is as defined in the embodiments and classes and subclasses herein.

[0150] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a cancer-causing agent comprising: 5A is phenylene, pyridinylene, or cyclohexynylene, thereby forming a group of formula II-1, III-1, IV-1, or V-1: [ka] [ka] or a pharmaceutically acceptable salt thereof, wherein in formula II-1, III-1, IV-1, and V-1, Cy A , Cy 6 , L 5 , L 6 , R 5B , R 5C , R W , and m are as defined in the embodiments and classes and subclasses herein.

[0151] In some embodiments, the present invention provides a method for the detection of Cy 6 is phenylene, pyridinylene, or pyrimidinylene, thereby providing a group of formula VI-1, VII-1, VIII-1, or IX-1: [ka] or a pharmaceutically acceptable salt thereof, wherein in formulas VI-1, VII-1, VIII-1, and IX-1, Cy A , L 6 , R 5 , R W , R 6 , and p are as defined in the embodiments and classes and subclasses herein.

[0152] In some embodiments, the present invention provides a method for the detection of Cy 6 is phenylene, thereby forming a ring of formula X-1, XI-1, XII-1, or XIII-1: [ka] or a pharmaceutically acceptable salt thereof, wherein in formula X-1, XI-1, XII-1, and XIII-1, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 , m, and p are as defined in the embodiments and classes and subclasses herein.

[0153] For example, in some embodiments, the present invention provides compounds of formula X-1, XI-1, XII-1, or XIII-1: [ka] [ka] or a pharmaceutically acceptable salt thereof, wherein in formulas X-1, XI-1, XII-1, and XIII-1: Cy A teeth, [ka] where Cy A of [ka] teeth, [ka] represents a bond to Cy A of [ka] teeth, [ka] represents a bond to; R 5B is hydrogen or R B where R 5B is n examples of R 5D is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of R A or R B where R 6 is the number of q examples in R C is replaced by; or R 6 Two examples of R 6One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; R 8 is H, -NR2, halogen, -OH, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 9 is H, -NR2, halogen, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 10 is H or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; L 5 and L 6 each independently represents a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L )-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; R WA , R WB, and R WC are independently hydrogen, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is a ring formed by combining the atoms between them to form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of R A or R B and u examples of R C is replaced by; R A each instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C and each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0154] In some embodiments, the present invention provides compounds of formula X-1, XI-1, XII-1, or XIII-1: [ka] or a pharmaceutically acceptable salt thereof, wherein in formulas X-1, XI-1, XII-1, and XIII-1: Cy A teeth, [ka] [ka] where Cy A of [ka] teeth, [ka] represents a bond to Cy A of [ka] teeth, [ka] represents a bond to; R 5B is hydrogen or R Bwhere R 5B is n examples of R 5D is replaced by; R W is a halogen, -CN, [ka] and; R 6 Each instance of A or R B where R 6 is the number of q examples in R C is replaced by; or R 6 Two examples of R 6 One example of R L together with the atoms therebetween to form a 4- to 7-membered partially unsaturated or aromatic ring having 0 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where the ring is one of r examples of R C is replaced by; R 7 is H or R B where R 7 Let's look at t examples of R 7A is replaced by; R 8 is H, -NR2, halogen, -OH, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 9 is H, -NR2, halogen, or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; R 10 is H or C optionally substituted with 1 to 3 halogens 1~6 It is aliphatic; L 5 and L 6 each independently represents a covalent bond, or C 1~4 wherein one or two methylene units of the chain are independently —CH(R L)-, -C(R L )2-, C 3~5 Cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O)2-, -N(R L )S(O)2-, -S(O)2NH-, -S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2- as appropriate; R WA , R WB , and R WC are independently hydrogen, deuterium, halogen, —CN, —C(O)R, —C(O)OR, —C(O)NR, —C(O)N(R)OR, or an optionally substituted group, wherein the optionally substituted group is C 1~6 selected from a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from aliphatic, phenyl, nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or R WA and R WB , R WB and R WC , R WA and R L One example of this is R WC and R L An example of is a ring formed by combining the atoms between them to form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O)R; R 5C , R 5D , R 7A , and R L Each instance of A or RB and u examples of R C is replaced by; R A each instance is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, or -N(R)S(O)2R; R B Each example of C 1~6 aliphatic; phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R C and each instance of is independently oxo, halogen, -CN, -NO2, -OR, -SR, -NR2, -S(O)2R, -S(O)2NR2, -S(O)R, -S(O)NR2, -S(O)2F, -OS(O)2F, -C(O)R, -C(O)OR, -C(O)NR2, -C(O)N(R)OR, -OC(O)R, -OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, -N(R)C(NR)NR2, -N(R)S(O)2NR2, -N(R)S(O)2R, or an optionally substituted group, wherein the optionally substituted group is C 1~6selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group, and the optionally substituted group is C 1~6 selected from aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4.

[0155] In some embodiments, the present invention provides a method for the detection of Cy 6 is pyridinylene, thereby forming a ring of formula XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, or XXI-1, respectively: [ka] [ka] or a pharmaceutically acceptable salt thereof, wherein in formula XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, and XXI-1, Cy A , L 5 , L 6 , R 5B , R5C , R W , R 6 , m, and p are as defined in the embodiments and classes and subclasses herein.

[0156] In some embodiments, the present invention provides a method for the detection of Cy 6 is pyrimidinylene, thereby forming a compound of formula XXII-1, XXIII-1, XXIV-1, or XXV-1, respectively: [ka] or a pharmaceutically acceptable salt thereof, wherein in Formula XXII-1, XXIII-1, XXIV-1, and XXV-1, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 , m, and p are as defined in the embodiments and classes and subclasses herein.

[0157] In some embodiments, the present invention provides a method for the detection of Cy A but, [ka] and wherein: [ka] is R 5 represents a bond to, and [ka] Cy 6 Represents a bond to

[0158] In some embodiments, the present invention provides a method for the detection of Cy A but, [ka] and wherein: [ka] is R 5 represents a bond to, and [ka] Cy 6 Represents a bond to

[0159] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a 5 is -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L )-. In some embodiments, the present invention provides a compound of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. 5is -O-. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein L is -O-. 5 is —C(O)—. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein L 5 is —C(O)NH—. In some embodiments, the present invention provides compounds of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein L 5 -C(O)N(R L )-, the formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, X A compound of III-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1 is provided.

[0160] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a 6 is -NH- or -N(R L)-. In some embodiments, the present invention provides a compound of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1. 6 is -NH-, formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, A compound of XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1 is provided.

[0161] In some embodiments, the invention provides a compound of Formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where m is 0 or 1. In some embodiments, the invention provides a compound of Formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where m is 0. In some embodiments, the invention provides a compound of Formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where m is 1.

[0162] In some embodiments, the invention provides a compound of Formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where p is 0 or 1. In some embodiments, the invention provides a compound of Formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where p is 0. In some embodiments, the invention provides a compound of Formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, where p is 1.

[0163] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a cancer-causing agent comprising: W but, [ka] In some embodiments, the present invention provides a compound of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein RW but, [ka] In some embodiments, the present invention provides a compound of formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XIII-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1, wherein R W but, [ka] , formula I-1, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, II-1, III-1, IV-1, V-1, VI-1, VII-1, VIII-1, IX-1, X-1, XI-1, XII-1, XI A compound of II-1, XIV-1, XV-1, XVI-1, XVII-1, XVIII-1, XIX-1, XX-1, XXI-1, XXII-1, XXIII-1, XXIV-1, or XXV-1 is provided.

[0164] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a cancer-causing agent comprising: 5A is phenylene, pyridinylene, or cyclohexynylene, thereby providing a group of formula II, III, IV, or V: [ka] or a pharmaceutically acceptable salt thereof, wherein in Formula II, III, IV, and V, Cy 6 , L 5 , L 6 , R 5B , R 5C , R W , R 7, and m are as defined in the embodiments and classes and subclasses herein.

[0165] In some embodiments, the present invention provides a method for the detection of Cy 6 is phenylene, pyridinylene, or pyrimidinylene, thereby providing a group of formula VI, VII, VIII, or IX: [ka] or a pharmaceutically acceptable salt thereof, wherein in formulas VI, VII, VIII, and IX, L 6 , R 5 , R W , R 6 , R 7 , and p are as defined in the embodiments and classes and subclasses herein.

[0166] In some embodiments, the present invention provides a method for the detection of Cy 6 is phenylene, thereby forming a ring of formula X, XI, XII, or XIII: [ka] or a pharmaceutically acceptable salt thereof, wherein in formulas X, XI, XII, and XIII, L 5 , L 6 , R 5B , R 5C , R W , R 6 , R 7 , m, and p are as defined in the embodiments and classes and subclasses herein.

[0167] In some embodiments, the present invention provides a method for the detection of Cy 6 is pyridinylene, thereby forming a ring of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, or XXI, respectively: [ka] [ka] or a pharmaceutically acceptable salt thereof, wherein in Formula XIV, XV, XVI, XVII, XVIII, XIX, XX, and XXI, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 , m, and p are as defined in the embodiments and classes and subclasses herein.

[0168] In some embodiments, the present invention provides a method for the detection of Cy 6 is pyrimidinylene, thereby forming a compound of formula XXII, XXIII, XXIV, or XXV, respectively: [ka] or a pharmaceutically acceptable salt thereof, wherein in Formula XXII, XXIII, XXIV, and XXV, Cy A , L 5 , L 6 , R 5B , R 5C , R W , R 6 , m, and p are as defined in the embodiments and classes and subclasses herein.

[0169] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a 5 is -O-, -C(O)-, -C(O)NH-, or -C(O)N(R LIn some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein L 5 In some embodiments, the present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein L is -O-. 5 In some embodiments, the present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein L is -C(O)-. 5 In some embodiments, the present invention provides compounds of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein L is -C(O)NH-. 5 -C(O)N(R L )-.

[0170] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a 6 is -NH- or -N(R L In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein L 6 is —NH—.

[0171] In some embodiments, the invention provides compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII where m is 0 or 1. In some embodiments, the invention provides compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII where m is 0. In some embodiments, the invention provides compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII where m is 1.

[0172] In some embodiments, the invention provides compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII where p is 0 or 1. In some embodiments, the invention provides compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII where p is 0. In some embodiments, the invention provides compounds of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII where p is 1.

[0173] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a cancer-causing agent comprising: W but, [ka] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein R W but, [ka] In some embodiments, the present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein R W but, [ka] The present invention provides a compound of formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, or XIII, wherein

[0174] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a 5 is -O-, -C(O)-, -C(O)NH-, or -C(O)N(R L In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein L 5 In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein L is -O-. 5 In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein L is —C(O)—. 5 In some embodiments, the present invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein L is —C(O)NH—. 5 -C(O)N(R L )-.

[0175] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a 6 is -NH- or -N(R L In some embodiments, the present invention provides a compound of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein L 6is —NH—.

[0176] In some embodiments, the invention provides compounds of Formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV where m is 0 or 1. In some embodiments, the invention provides compounds of Formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV where m is 0. In some embodiments, the invention provides compounds of Formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV where m is 1.

[0177] In some embodiments, the invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV where p is 0 or 1. In some embodiments, the invention provides compounds of XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV where p is 0. In some embodiments, the invention provides compounds of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV where p is 1.

[0178] In some embodiments, the present invention provides a method for treating a cancer comprising administering to a subject a cancer-causing agent comprising: W but, [ka] In some embodiments, the present invention provides a compound of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein R W but, [ka] In some embodiments, the present invention provides a compound of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein R W but, [ka] The present invention provides a compound of formula XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, or XXV, wherein

[0179] Examples of compounds of the present invention include the compounds listed in the tables and examples herein, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention encompasses a compound selected from those depicted in Table 1 below, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof. In some embodiments, the present invention provides a compound set forth in Table 1 below, or a pharmaceutically acceptable salt thereof. In some embodiments, the present invention provides a compound set forth in Table 1 below. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7]

Table 1-8

Table 1-9

Table 1-10

Table 1-11

Table 1-12

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

Table 1-27

Table 1-28

Table 1-29

Table 1-30

Table 1-31

Table 1-32

Table 1-33

Table 1-34

Table 1-35

Table 1-36

Table 1-37

Table 1-38

Table 1-39

Table 1-40

Table 1-41

Table 1-42

Table 1-43

Table 1-44

Table 1-45

Table 1-46

Table 1-47

Table 1-48

Table 1-49

Table 1-50

Table 1-51

Table 1-52

Table 1-53

Table 1-54

Table 1-55

Table 1-56

Table 1-57

Table 1-58

Table 1-59

Table 1-60

Table 1-61

Table 1-62

Table 1-63

Table 1-64

Table 1-65

Table 1-66

Table 1-67

Table 1-68

Table 1-69

Table 1-70

Table 1-71

Table 1-72

Table 1-73

Table 1-74

Table 1-75

Table 1-76

Table 1-77

Table 1-79

Table 1-80

Table 1-81

Table 1-82

Table 1-83

Table 1-84

Table 1-85

Table 1-86

Table 1-87

Table 1-88

Table 1-89

Table 1-90

Table 1-91

Table 1-92

Table 1-93

Table 1-94

Table 1-95

Table 1-96

Table 1-97

Table 1-98

Table 1-99

Table 1-100

Table 1-101

Table 1-103

Table 1-104

Table 1-105

Table 1-106

Table 1-108

Table 1-109

Table 1-110

Table 1-111

Table 1-112

Table 1-113

Table 1-114

Table 1-115

Table 1-116

Table 1-117

Table 1-118

Table 1-119

Table 1-120

Table 1-121

Table 1-123

Table 1-124

Table 1-125

Table 1-126

Table 1-127

Table 1-129

Table 1-131

Table 1-133

Table 1-136

Table 1-137

Table 1-138

Table 1-139

Table 1-141

Table 1-145

Table 1-147

Table 1-149

Table 1-150

Table 1-151

Table 1-152

Table 1-153

Table 1-155

Table 1-156

Table 1-157

Table 1-158

Table 1-159

Table 1-161

Table 1-166

Table 1-171

Table 1-176

Table 1-177

Table 1-179

Table 1-189

Table 1-191

Table 1-195

Table 1-197

Table 1-198

Table 1-199

Table 1-200

Table 1-201

Table 1-202

Table 1-203

Table 1-204

Table 1-205

Table 1-207

Table 1-209

Table 1-211

Table 1-212

Table 1-213

Table 1-215

Table 1-217

Table 1-219

Table 1-220

Table 1-221

Table 1-222

Table 1-223

Table 1-225

Table 1-226

Table 1-227

Table 1-228

Table 1-229

Table 1-231

Table 1-236

Table 1-237

Table 1-239

Table 1-245

Table 1-246

Table 1-249

Table 1-250

Table 1-251

Table 1-252

Table 1-253

Table 1-254

Table 1-256

Table 1-257

Table 1-258

Table 1-259

Table 1-261

Table 1-263

Table 1-269

Table 1-271

Table 1-276

Table 1-277

Table 1-279

Table 1-283

Table 1-288

Table 1-289

Table 1-291

Table 1-300

Table 1-303

Table 1-304

Table 1-305

Table 1-306

Table 1-309

Table 1-311

Table 1-313

Table 1-315

Table 1-316

Table 1-317

Table 1-319

Table 1-321

Table 1-323

Table 1-325

Table 1-326

Table 1-327

Table 1-329

Table 1-331

Table 1-333

Table 1-334

Table 1-335

Table 1-336

Table 1-337

Table 1-338

Table 1-339

[0180] In the chemical structures in Table 1 above, if a stereocenter is depicted with a dashed or wedge bond and labeled "abs" (or not labeled), the compound is essentially a single isomer at this stereocenter (rather than an equimolar mixture), and the absolute stereochemistry is indicated in the chemical structure (see, e.g., the structure of Example 146). If a stereocenter is depicted with a dashed or wedge bond and labeled "or 1," the compound is a single isomer at this stereocenter, but the absolute stereochemistry at this stereocenter has not been determined (see, e.g., the structures of Examples 397 and 398). If a stereocenter is depicted with a dashed or wedge bond and labeled "and1" or "&1," the compound is a mixture of two isomers at this stereocenter, i.e., the depicted structure and an isomer having the opposite configuration at the stereogenic center (see, e.g., the structure of Example 581).

[0181] Certain compounds depicted in Table 1 above exist as liquids at room temperature as atropisomers that do not interconvert across the biaryl bond. When one of the atoms in the biaryl bond is labeled "or 1," this indicates that the compound exists as a liquid at room temperature as atropisomers that do not interconvert, and that the compound is essentially a single atropisomer (rather than an equimolar mixture) (see, for example, the structures of Examples 516 and 517).

[0182] In some embodiments, the present invention provides a method for treating FGFR2 in a mammalian animal, comprising administering to a mammalian animal the compound of formula "A" in a Biochemical FGFR2 Caliper IC 50 In some embodiments, the present invention provides a compound of Table 1 above, wherein the compound is a Biochemical FGFR2 Caliper IC of "A" or "B". 50 In some embodiments, the present invention provides a compound of Table 1 above, wherein the compound is described as having a Biochemical FGFR2 Caliper IC of "A" or "B" or "C." 50The compound of Table 1 above is described as having the formula:

[0183] In some embodiments, the present invention relates to a compound "A" in the cell SNU-16 IC 50 In some embodiments, the present invention provides a compound of Table 1 above, wherein the compound is a SNU-16 cell IC of "A" or "B." 50 In some embodiments, the present invention provides a compound of Table 1 above, wherein the compound is a SNU-16 cell IC of "A" or "B" or "C." 50 The compound of Table 1 above is described as having the formula: 4. General Methods of Providing the Compounds

[0184] The compounds of the invention may generally be prepared or isolated by synthetic and / or semi-synthetic methods known to those skilled in the art for similar compounds, as well as by methods described in detail in the Examples herein. 5. Use, Prescription and Administration Pharmaceutically Acceptable Compositions

[0185] According to another embodiment, the present invention provides a composition comprising a compound of the present invention, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier. The amount of the compound in the composition of the present invention is an amount effective to measurably inhibit FGFR2 protein kinase or a mutant thereof in a biological sample or in a patient. In certain embodiments, the amount of the compound in the composition of the present invention is an amount effective to measurably inhibit FGFR2 protein kinase or a mutant thereof in a biological sample or in a patient. In certain embodiments, the composition of the present invention is formulated for administration to a patient in need of such a composition. In some embodiments, the composition of the present invention is formulated for oral administration to a patient.

[0186] The terms "subject" and "patient," as used herein, refer to an animal (i.e., a member of the animal kingdom), preferably a mammal, and most preferably a human. In some embodiments, the subject is a human, a mouse, a rat, a cat, a monkey, a dog, a horse, or a pig. In some embodiments, the subject is a human. In some embodiments, the subject is a mouse, a rat, a cat, a monkey, a dog, a horse, or a pig.

[0187] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants, or vehicles that can be used in the compositions of this invention include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, electrolytes such as salts or protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.

[0188] "Pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, directly or indirectly, the compound of this invention or an inhibitory active metabolite or residue thereof.

[0189] As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of FGFR2 protein kinase or a mutant thereof.

[0190] The compositions of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally, or intravenously.

[0191] The sterile injectable form of the composition of this invention may be an aqueous or oily suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media.

[0192] For this purpose, any bland fixed oil can be used, including synthetic monoglycerides or diglycerides.Fatty acids such as oleic acid and its glyceride derivatives, especially in their polyoxyethylated form, are useful for preparing injectable substances, as are natural pharmaceutically acceptable oils such as olive oil or castor oil.These oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, which are commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions or suspensions.Other commonly used surfactants, such as Tween, Span, and other emulsifiers or bioavailability enhancers, which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms, can also be used for formulation purposes.

[0193] The pharmaceutically acceptable composition of this invention can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions.For tablets for oral use, commonly used carriers include lactose and corn starch.Lubricants such as magnesium stearate are also typically added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifiers and suspending agents.If desired, certain sweeteners, flavorings or coloring agents can also be added.

[0194] Alternatively, the pharmaceutically acceptable compositions of this invention can be administered in the form of suppositories for rectal or vaginal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal or vaginal temperature and therefore melts in the rectum or vagina to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.

[0195] The pharmaceutically acceptable compositions of this invention may also be administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[0196] Topical application for the lower intestinal tract may be in a rectal suppository formulation (see above) or in a suitable enema formulation. Topical-transdermal patches may also be used.

[0197] For topical application, the provided pharmaceutically acceptable composition can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers.Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid paraffin, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water.Alternatively, the provided pharmaceutically acceptable composition can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers.Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0198] For ophthalmic use, the provided pharmaceutically acceptable compositions can be formulated as a micronized suspension in isotonic, pH-adjusted, sterile saline, or preferably as a solution in isotonic, pH-adjusted, sterile saline, with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutically acceptable compositions can be formulated into an ointment such as petrolatum.

[0199] The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation, and may be prepared as solutions in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.

[0200] Preferably, the pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, the pharmaceutically acceptable compositions of this invention are administered with food.

[0201] The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending on the patient being treated and the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01 and 100 mg of inhibitor per kg of body weight per day can be administered to a patient receiving these compositions.

[0202] It should also be understood that the specific dosage and treatment regimen for any particular patient will vary depending on a variety of factors, including the activity of the specific compounds employed, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, as well as the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the invention in a composition will also vary depending on the particular compound in the composition.

[0203] The precise dose to be employed in the compositions will also depend on the route of administration and should be decided according to the judgment of the practitioner and each subject's circumstances. In specific embodiments of the present disclosure, suitable doses for oral administration of the compounds of the present disclosure are generally from about 1 mg / day to about 1000 mg / day. In some embodiments, the oral dose is from about 1 mg / day to about 800 mg / day. In some embodiments, the oral dose is from about 1 mg / day to about 500 mg / day. In some embodiments, the oral dose is from about 1 mg / day to about 250 mg / day. In some embodiments, the oral dose is from about 1 mg / day to about 100 mg / day. In some embodiments, the oral dose is from about 5 mg / day to about 50 mg / day. In some embodiments, the oral dose is about 5 mg / day. In some embodiments, the oral dose is about 10 mg / day. In some embodiments, the oral dose is about 20 mg / day. In some embodiments, the oral dose is about 30 mg / day. In some embodiments, the oral dose is about 40 mg / day. In some embodiments, the oral dose is about 50 mg / day. In some embodiments, the oral dose is about 60 mg / day. In some embodiments, the oral dose is about 70 mg / day. In some embodiments, the oral dose is about 100 mg / day. It is recognized that any of the dosage amounts recited herein may constitute higher or lower dosage ranges and may be combined with any other dosage amount to form a dosage range inclusive of upper and lower limits.

[0204] In some embodiments, a pharmaceutically acceptable composition contains a provided compound and / or a pharmaceutically acceptable salt thereof at a concentration ranging from about 0.01 to about 90 wt%, about 0.01 to about 80 wt%, about 0.01 to about 70 wt%, about 0.01 to about 60 wt%, about 0.01 to about 50 wt%, about 0.01 to about 40 wt%, about 0.01 to about 30 wt%, about 0.01 to about 20 wt%, about 0.01 to about 2.0 wt%, about 0.01 to about 1 wt%, about 0.05 to about 0.5 wt%, about 1 to about 30 wt%, or about 1 to about 20 wt%. The composition may be formulated as a solution, suspension, ointment, capsule, or the like. The pharmaceutical composition may be prepared as an aqueous solution and may contain additional ingredients such as preservatives, buffers, isotonicity agents, antioxidants, stabilizers, and viscosity adjusting ingredients.

[0205] Pharmaceutically acceptable carriers are well known to those skilled in the art and include, for example, adjuvants, diluents, excipients, fillers, lubricants, and vehicles. In some embodiments, the carrier is a diluent, adjuvant, excipient, or vehicle. In some embodiments, the carrier is a diluent, adjuvant, or excipient. In some embodiments, the carrier is a diluent or adjuvant. In some embodiments, the carrier is an excipient.

[0206] Examples of pharmaceutically acceptable carriers may include, for example, water or saline solution, polymers such as polyethylene glycol, carbohydrates and their derivatives, oils, fatty acids, or alcohols.Non-limiting examples of oils as pharmaceutical carriers include oils of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil.Pharmaceutical carriers may also be saline, acacia gum, gelatin, starch paste, talc, keratin, colloidal silica, and urea.In addition, auxiliary agents, stabilizers, thickeners, lubricants, and colorants may be used.Other examples of suitable pharmaceutical carriers can be found, for example, in Remington's: The Science and Practice of Pharmacy, 22nd Ed. (Allen, Loyd V., Jr ed., Pharmaceutical Press (2012)); Modern Pharmaceutics, 5 th Ed.(Alexander T.Florence,Juergen Siepmann,CRC Press(2009));Handbook of Pharmaceutical Excipients,7 th Ed. (Rowe, Raymond C.; Sheskey, Paul J.; Cook, Walter G.; Fenton, Marian E. eds., Pharmaceutical Press (2012)), each of which is incorporated herein by reference in its entirety.

[0207] As used herein, pharmaceutically acceptable carriers can be selected from a variety of organic or inorganic materials used as materials for pharmaceutical formulations and incorporated as analgesics, buffers, binders, disintegrants, diluents, emulsifiers, excipients, bulking agents, glidants, solubilizers, stabilizers, suspending agents, isotonicity agents, vehicles, and thickeners. Pharmaceutical additives such as antioxidants, flavoring agents, coloring agents, flavor improvers, preservatives, and sweeteners can also be added. Examples of acceptable pharmaceutical carriers include carboxymethylcellulose, crystalline cellulose, glycerin, gum arabic, lactose, magnesium stearate, methylcellulose, powder, saline, sodium alginate, sucrose, starch, talc, and water, among others. In some embodiments, the term "pharmaceutically acceptable" means approved by a federal or national government regulatory agency or listed in the United States Pharmacopoeia or other generally recognized pharmacopeia for use in animals, more particularly in humans.

[0208] Surfactants such as detergents are also suitable for use in the formulation.Specific examples of surfactants include polyvinylpyrrolidone, polyvinyl alcohol, vinyl acetate copolymers and vinylpyrrolidone copolymers, polyethylene glycol, benzyl alcohol, mannitol, glycerol, sorbitol, or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic acid derivatives such as methacrylates; anionic surfactants such as alkaline stearates, especially sodium stearate, potassium stearate, or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, especially sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulfonate or sodium dioctyl sulfosuccinate; or fatty acids, especially those derived from coconut oil; cationic surfactants such as those of the formula N + R'R''R'''R''''Y -wherein the R radicals are the same or different optionally substituted hydroxylated hydrocarbon radicals, and Y - is an anion of a strong acid, such as a halide anion, sulfate anion, and sulfonate anion; cetyltrimethylammonium bromide is one cationic surfactant that can be used; + Amine salts of R'R''R''' (where the R radicals are the same or different, optionally substituted hydroxylated hydrocarbon radicals); octadecylamine hydrochloride is one of the cationic surfactants that can be used; nonionic surfactants, such as optionally polyoxyethylated esters of sorbitan, especially polysorbate 80, or polyoxyethylated alkyl ethers; polyethylene glycol stearate, polyoxyethylated derivatives of castor oil, polyglycerol esters, polyoxyethylated fatty alcohols, polyoxyethylated fatty acids, or copolymers of ethylene oxide and propylene oxide; amphoteric surfactants, such as substituted lauryl compounds of betaine.

[0209] Suitable pharmaceutical carriers may also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, polyethylene glycol 300, water, ethanol, and polysorbate 20. The composition, if desired, can also contain wetting or emulsifying agents, or pH buffering agents.

[0210] Tablet and capsule preparations can contain one or more adjuvants, binders, diluents, disintegrants, excipients, fillers or lubricants, each of which is known in the art.Examples of such include carbohydrates such as lactose or sucrose, anhydrous calcium hydrogen phosphate, corn starch, mannitol, xylitol, cellulose or its derivatives, microcrystalline cellulose, gelatin, stearate, silicon dioxide, talc, sodium starch glycolate, acacia, flavoring agents, preservatives, buffering agents, disintegrating agents, and coloring agents.Oral administration composition can contain one or more necessary agents, such as sweeteners such as fructose, aspartame or saccharin; flavoring agents such as peppermint, sedge oil, or cherry; coloring agents; and preservatives, etc., to provide pharmaceutically palatable preparations. Uses of the Compounds and Pharmaceutically Acceptable Compositions

[0211] The compounds and compositions described herein are generally useful for inhibiting kinases or their mutants.In some embodiments, the kinase inhibited by the compounds and compositions described herein is fibroblast growth factor receptor (FGFR).In some embodiments, the kinase inhibited by the compounds and compositions described herein is one or more of FGFR1, FGFR2, FGFR3, and FGFR4.In some embodiments, the kinase inhibited by the compounds and compositions described herein is FGFR2.

[0212] The compounds or compositions of the present disclosure may be useful in applications that benefit from inhibition of the FGFR2 enzyme. For example, the FGFR2 inhibitors of the present invention are generally useful for the treatment of proliferative disorders.

[0213] Activation of FGFR2 gene fusions has been detected in numerous cancers, including intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, squamous cell lung carcinoma, thyroid cancer, gastric cancer, and ovarian cancer (IS Babina and NC Turner, Nat. Rev. Cancer 2017, 17:318-332; YM Wu, et al. Cancer Discov. 3:636-647; and references incorporated herein).

[0214] FGFR2 amplification has been described in gastric cancer, breast cancer, triple-negative breast cancer, and rectal cancer (I.S. Babina and N.C. Turner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; and references incorporated therein).

[0215] Activation of FGFR2 mutants has been detected in endometrial cancer, non-small cell lung cancer, lung squamous cell carcinoma, gastric cancer, breast cancer and urothelial cancer.The most common mutations include mutations in intracellular kinase domain (such as N549K and K659N / M) and mutations in extracellular domain (S252W and P253R).The resistance mutations that occur in FGFR2 from treatment with pan-FGFR1-3 inhibitors can also be targeted with FGFR2 inhibitors. These include V564F, E565A, N549K / H / T, and L617V (I.S. Babina and N.C. Turner, Nat. Rev. Cancer 2017, 17:318-332; M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; R. Porta, et al. Crit. Rev. Oncol. Hematol. 2017, 113:256-267; and references incorporated therein).

[0216] Inhibition of FGFR2 also has antitumor activity in tumors with increased expression of FGFR2 ligands (FGF1-4, 7, 8, 10, 21-23) (N. Turner and R. Grose, Nat. Rev. Cancer 2010, 10:116-129; and references incorporated therein).

[0217] Inhibition of FGFR2 also has anti-tumor activity in tumors with amplification or overexpression of the FGFR adaptor protein, FRS2 (IS Babina and NC Turner, Nat. Rev. Cancer 2017, 17:318-332; and references incorporated therein).

[0218] Selective inhibition of FGFR2 can be generally effective in the indications that pan-FGFR1-3 inhibitors are effective.Such indications are described in I.S. Babina and N.C. Turner, Nat.Rev.Cancer 2017,17:318-332; M. Katoh, Nat.Rev.Clin.Oncol.2019,16:105-122; R. Porta, et al., Crit.Rev.Oncol.Hematol.2017,113:256-267; and the references cited therein.

[0219] Activating mutations in FGFR2 have also been detected in craniosynostotic syndromes, including Crouzon, Appert, Peiffel, Antley-Bixler, Bear-Stevenson cutis gyrate, Jackson-Weiss, kyphotic dysplasia, and Seathre-Chotzen-like syndromes, which result in premature fusion of cranial sutures (SC Azoury, et al. Int. J. Biol. Sci. 2017, 13:1479-1488; and references incorporated therein). Inhibition of FGFR2 is also effective in these craniosynostotic syndromes.

[0220] The activity of compounds utilized herein as degraders and / or inhibitors of FGFR kinases, such as FGFR2 or its mutants, can be assayed in vitro, in vivo, or in cell lines. In vitro assays include assays that determine inhibition of either the phosphorylation activity and / or subsequent functional consequences, or the ATPase activity, of activated FGFR2 or its mutants. An alternative in vitro assay quantifies the ability of an inhibitor to bind to FGFR2. Inhibitor binding can be measured by radiolabeling the inhibitor prior to binding, isolating the inhibitor / FGFR2 complex, and determining the amount of bound radiolabel. Alternatively, inhibitor binding can be determined by performing a competition experiment in which a new inhibitor is incubated with FGFR2 bound to a known radioligand. Representative in vitro and in vivo assays useful for assaying FGFR2 inhibitors include those described and disclosed in the patents and scientific publications cited herein. Detailed conditions for assaying compounds utilized in the present invention as inhibitors of FGFR2 or its mutants are described in the Examples below. Treatment of the problem

[0221] The provided compounds are inhibitors of FGFR2 and are therefore useful for treating one or more disorders associated with the activity of FGFR2 or its mutants. Accordingly, in certain embodiments, the present invention provides a method for treating a disorder mediated by FGFR2 in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition of any of the foregoing. In certain embodiments, the present invention provides a method for treating a disorder mediated by FGFR2 in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable composition thereof.

[0222] As used herein, the term "FGFR2-mediated" disorder, disease, and / or condition refers to any disease or other deleterious condition in which FGFR2 or its variants are known to play a role. Accordingly, another embodiment of the present invention relates to treating or reducing the severity of one or more diseases in which FGFR2 or its variants are known to play a role. Such FGFR2-mediated disorders include, but are not limited to, proliferative disorders (e.g., cancer) and craniosynostosis syndrome.

[0223] In some embodiments, the present invention provides methods for treating one or more disorders, wherein the disorders are selected from a proliferative disorder and craniosynostosis syndrome, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition of any of the foregoing. In some embodiments, the present invention provides methods for treating one or more disorders, wherein the disorders are selected from a proliferative disorder and craniosynostosis syndrome, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable composition thereof.

[0224] In some embodiments, the present invention provides a method for treating a disorder in a subject, the method comprising administering a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any of the above, to a subject in need thereof, wherein the disorder is cholangiocarcinoma, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, or urothelial cancer. In some embodiments, the disorder is intrahepatic cholangiocarcinoma. In some embodiments, the disorder is hepatocellular carcinoma. In some embodiments, the disorder is squamous cell lung carcinoma or non-small cell lung cancer.

[0225] In some embodiments, the disorder is cholangiocarcinoma. In some embodiments, the cholangiocarcinoma is intrahepatic cholangiocarcinoma. In some embodiments, the disorder is liver cancer. In some embodiments, the liver cancer is hepatocellular carcinoma. In some embodiments, the disorder is lung cancer. In some embodiments, the lung cancer is lung squamous cell carcinoma or non-small cell lung cancer.

[0226] In some embodiments, the present invention provides a method for treating intrahepatic cholangiocarcinoma in a subject, comprising administering a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or any of the above pharmaceutical compositions to a subject in need thereof. In some embodiments, the present invention provides a method for treating hepatocellular carcinoma in a subject, comprising administering a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or any of the above pharmaceutical compositions to a subject in need thereof. In some embodiments, the present invention provides a method for treating lung squamous cell carcinoma or non-small cell lung cancer in a subject, comprising administering a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, or any of the above pharmaceutical compositions to a subject in need thereof.

[0227] In some embodiments, the disorder is associated with FGFR2 signaling. FGFR2 and other receptor tyrosine kinases (RTKs) are known to have multiple upstream and downstream signaling pathways (see Turner and Grose, Nat. Rev. Cancer (2010) 10, 116), and inhibition of FGFR2 can be used to treat disorders associated with abnormal signaling in these pathways. In some embodiments, the disorder is associated with FGF signaling, JAK-STAT signaling, PI3K-Akt signaling, PLC-γ signaling, or MAPK signaling.

[0228] In some embodiments, the method of treatment includes the steps of: i) identifying a subject in need of such treatment; (ii) providing a disclosed compound, or a pharmaceutically acceptable salt thereof; and (iii) administering the provided compound in a therapeutically effective amount to treat, inhibit, and / or prevent a disease state or condition in the subject in need of such treatment.

[0229] In some embodiments, the method of treatment includes the steps of: i) identifying a subject in need of such treatment; (ii) providing a composition containing a disclosed compound, or a pharmaceutically acceptable salt thereof; and (iii) administering the composition in a therapeutically effective amount to treat, inhibit, and / or prevent a disease state or condition in the subject in need of such treatment.

[0230] Another aspect of the present invention provides a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any of the above, for use in treating the disorders described herein. Another aspect of the present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any of the above, for the treatment of the disorders described herein. Similarly, the present invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of the disorders described herein. Proliferative disorders

[0231] In some embodiments, the disorder is a proliferative disorder. In some embodiments, the proliferative disorder is cancer. In some embodiments, the proliferative disorder is leukemia, breast cancer, lung cancer, colorectal cancer, or a combination thereof. In some embodiments, the proliferative disorder is leukemia. In some embodiments, the proliferative disorder is breast cancer. In some embodiments, the proliferative disorder is lung cancer. In some embodiments, the proliferative disorder is colorectal cancer.

[0232] In some embodiments, the proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, lung squamous cell carcinoma, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, non-small cell lung cancer, or urothelial cancer. In some embodiments, the proliferative disorder is intrahepatic cholangiocarcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, lung squamous cell carcinoma, thyroid cancer, gastric cancer, or ovarian cancer. In some embodiments, the proliferative disorder is gastric cancer, breast cancer, triple-negative breast cancer, or rectal cancer. In some embodiments, the proliferative disorder is endometrial cancer, non-small cell lung cancer, lung squamous cell carcinoma, gastric cancer, breast cancer, or urothelial cancer.

[0233] In some embodiments, the proliferative disorder is associated with one or more activating mutations in FGFR2. In some embodiments, the activating mutation in FGFR2 is a mutation in one or more of the intracellular kinase domain and the extracellular domain. In some embodiments, the activating mutation in FGFR2 is a mutation in the intracellular kinase domain. In some embodiments, the activating mutation in FGFR2 is a mutation in the extracellular domain. In some embodiments, the activating mutation in FGFR2 is selected from N549K, K659N / M, S252W, P253R, and combinations thereof. In some embodiments, the activating mutation in FGFR2 is N549K or K659N / M. In some embodiments, the activating mutation in FGFR2 is N549K. In some embodiments, the activating mutation in FGFR2 is K659N / M. In some embodiments, the activating mutation in FGFR2 is S252W or P253R. In some embodiments, the activating mutation in FGFR2 is S252W. In some embodiments, the activating mutation in FGFR2 is P253R.

[0234] In some embodiments, the proliferative disorder is associated with one or more resistance mutations in FGFR2. In some embodiments, the resistance mutation in FGFR2 is selected from V564F, E565A, N549K / H / T, and L617V, and combinations thereof. In some embodiments, the resistance mutation in FGFR2 is V564F. In some embodiments, the resistance mutation in FGFR2 is E565A. In some embodiments, the resistance mutation in FGFR2 is N549K / H / T. In some embodiments, the resistance mutation in FGFR2 is L617V. Route of administration and dosage form

[0235] The compounds and compositions according to the method of the present invention can be administered in any amount and by any route of administration effective for treating or reducing the severity of a disorder (e.g., a proliferative disorder or craniosynostosis syndrome). The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the specific drug, its mode of administration, etc. The compounds of the present invention are preferably formulated into unit dosage forms for ease of administration and uniformity of dosage. The term "unit dosage form" as used herein refers to a physically discrete unit of drug appropriate for the patient to be treated. However, it is understood that the total daily usage amount of the compounds and compositions of the present invention will be determined by the attending physician within the scope of sound medical judgment. The effective dosage level specific to any particular patient or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound used; the specific composition used; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound used; the duration of treatment; drugs used in combination or concomitantly with the specific compound used, and similar factors well known in the medical arts.

[0236] The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, as an oral or nasal spray, etc. In certain embodiments, the compounds of this invention can be administered orally or parenterally at dosage levels of about 0.01 mg to about 50 mg per kg, preferably about 1 mg to about 25 mg per kg, of subject body weight per day, one or more times daily to achieve the desired therapeutic effect.

[0237] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to active compounds, liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, oral compositions may also contain adjuvants such as wetting agents, emulsifiers and suspending agents, as well as sweeteners, flavoring agents and fragrances.

[0238] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be injectable sterile solutions, suspensions, or emulsions in non-toxic, parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, USP, and isotonic sodium chloride solution. Additionally, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oil, including synthetic monoglycerides or diglycerides, may be used. Additionally, fatty acids, such as oleic acid, are used in the preparation of injectables.

[0239] Injectable preparations can be sterilized prior to use, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other injectable sterile medium.

[0240] To prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This can be accomplished by using a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends on its dissolution rate, which in turn may depend on crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form can be achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. The compound release rate can be controlled depending on the ratio of compound to polymer and the nature of the particular polymer used. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations can also be prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[0241] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing a compound of this invention with a suitable non-irritating excipient or carrier such as cocoa butter, polyethylene glycol or a suppository wax which is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active compound.

[0242] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) humectants such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0243] Solid compositions of a similar type may also be used as fillers for soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols, etc. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be composed so that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be used as fillers for soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols, etc.

[0244] The active compound may be in microencapsulated form with one or more of the excipients described above. Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings, release-controlling coatings, and other coatings well known in the pharmaceutical formulation art. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, such as sucrose, lactose, or starch. As is common practice, such dosage forms may contain additional substances other than inert diluents, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms may also contain buffering agents. They may optionally contain opacifying agents, and may be of a composition that releases the active ingredient(s) only or preferentially in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[0245] Dosage forms for topical or transdermal administration of the compounds of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers, as needed. Ophthalmic formulations, ear drops, and eye drops are also contemplated within the scope of this invention. Furthermore, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispersing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel. Dosage and Regimen

[0246] According to one embodiment, the present invention relates to a method of inhibiting protein kinase activity in a biological sample, comprising the step of contacting said biological sample with a compound of this invention or a composition comprising said compound.

[0247] In some embodiments, these methods include administering a therapeutically effective dosage of a compound of the present disclosure. In some embodiments, the therapeutically effective dosage is at least about 0.0001 mg / kg body weight, at least about 0.001 mg / kg body weight, at least about 0.01 mg / kg body weight, at least about 0.05 mg / kg body weight, at least about 0.1 mg / kg body weight, at least about 0.25 mg / kg body weight, at least about 0.3 mg / kg body weight, at least about 0.5 mg / kg body weight, at least about 0.75 mg / kg body weight, at least about 1 mg / kg body weight, at least about 2 mg / kg body weight, at least about 3 mg / kg body weight, at least about 4 mg / kg body weight, at least about 5 mg / kg body weight, at least about 6 mg / kg body weight, at least about 7 mg / kg body weight, at least about 8 mg / kg body weight, at least about 9 mg / kg body weight, at least about 10 mg / kg body weight, at least about 15 mg / kg body weight, at least about 20 mg / kg body weight, at least about 25 mg / kg body weight, at least about 30 mg / kg body weight, at least about 40 mg / kg body weight, at least about 50 mg / kg body weight, at least about 75 mg / kg body weight, at least about 100 mg / kg body weight, at least about 200 mg / kg body weight, at least about 250 mg / kg body weight, at least about 300 mg / kg body weight, at least about 350 mg / kg body weight, at least about 400 mg / kg body weight, at least about 450 mg / kg body weight, at least about 500 mg / kg body weight, at least about 550 mg / kg body weight, at least about 600 mg / kg body weight, at least about 650 mg / kg body weight, at least about 700 mg / kg body weight, at least about 750 mg / kg body weight, at least about 800 mg / kg body weight, at least about 900 mg / kg body weight, or at least about 1000 mg / kg body weight. It is recognized that any of the dosage amounts recited herein may constitute higher or lower dosage ranges, and may be combined with any other dosage amount to form a dosage range with a higher upper limit and a lower lower limit.

[0248] In some embodiments, the therapeutically effective dosage is within the range of about 0.1 mg to about 10 mg / kg body weight, about 0.1 mg to about 6 mg / kg body weight, about 0.1 mg to about 4 mg / kg body weight, or about 0.1 mg to about 2 mg / kg body weight.

[0249] In some embodiments, the therapeutically effective dosage is within the range of about 1 to 500 mg, about 2 to 150 mg, about 2 to 120 mg, about 2 to 80 mg, about 2 to 40 mg, about 5 to 150 mg, about 5 to 120 mg, about 5 to 80 mg, about 10 to 150 mg, about 10 to 120 mg, about 10 to 80 mg, about 10 to 40 mg, about 20 to 150 mg, about 20 to 120 mg, about 20 to 80 mg, about 20 to 40 mg, about 40 to 150 mg, about 40 to 120 mg, or about 40 to 80 mg.

[0250] In some embodiments, the methods involve a single dosage or administration (e.g., as a single injection or deposition). Alternatively, in some embodiments, the methods involve administration once daily, twice daily, three times daily, or four times daily to a subject in need thereof for about 2 days to about 28 days, or about 7 days to about 10 days, or about 7 days to about 15 days, or longer. In some embodiments, the methods involve chronic administration. In still other embodiments, the methods involve administration over the course of weeks, months, years, or decades. In still other embodiments, the methods involve administration over the course of weeks. In still other embodiments, the methods involve administration over the course of months. In still other embodiments, the methods involve administration over the course of years. In still other embodiments, the methods involve administration over the course of decades.

[0251] The dosage administered may vary depending on known factors such as the pharmacokinetic properties of the active ingredient and its mode and route of administration; the time of administration of the active ingredient; the age, sex, health, and weight of the recipient; the nature and extent of the symptoms; the type of concurrent treatment, frequency of treatment, and the desired effect; and the rate of excretion, all of which can be readily determined and used by those skilled in the art to adjust or titrate the dosage and / or dosing regimen. Protein kinase inhibition

[0252] According to one embodiment, the present invention relates to a method of inhibiting protein kinase activity in a biological sample, comprising the step of contacting said biological sample with a compound of this invention or a composition comprising said compound.

[0253] According to another embodiment, the present invention relates to a method for inhibiting the activity of FGFR2 or a mutant thereof in a biological sample, comprising the step of contacting said biological sample with a compound of this invention or a composition comprising said compound. According to a particular embodiment, the present invention relates to a method for reversibly inhibiting the activity of FGFR2 or a mutant thereof in a biological sample, comprising the step of contacting said biological sample with a compound of this invention or a composition comprising said compound. According to a particular embodiment, the present invention relates to a method for irreversibly inhibiting the activity of FGFR2 or a mutant thereof in a biological sample, comprising the step of contacting said biological sample with a compound of this invention or a composition comprising said compound.

[0254] In some embodiments, the present invention relates to a method for irreversibly inhibiting FGFR2, or a mutant thereof, wherein the compound of the present invention forms a covalent bond with FGFR2, or a mutant thereof. ... Wand a cysteine ​​of FGFR2 or a mutant thereof. In some embodiments, the present invention relates to a method of irreversibly inhibiting FGFR2 or a mutant thereof, wherein the compound of the present invention forms a covalent bond between the R W and forms a covalent bond with Cys491 of FGFR2 or its mutant.

[0255] In another embodiment, the present invention relates to FGFR2, or variants thereof, that are irreversibly inhibited by the compounds of the present invention. In some embodiments, the present invention relates to FGFR2, or variants thereof, that are covalently bound to the compounds of the present invention. In some embodiments, the present invention relates to FGFR2, or variants thereof, that are covalently bound to the compounds of the present invention, wherein the covalent bond is at the R W and a cysteine ​​of FGFR2 or a variant thereof. In some embodiments, the present invention relates to FGFR2, or a variant thereof, covalently linked to a compound of the present invention, wherein the covalent bond is between R of the compound W and Cys491 of FGFR2 or its mutants.

[0256] In another embodiment, the present invention provides a method for selectively inhibiting FGFR2 over one or more of FGFR1, FGFR3, and FGFR4. In some embodiments, compounds of the present invention are more than 5-fold selective over FGFR1, FGFR3, and FGFR4. In some embodiments, compounds of the present invention are more than 10-fold selective over FGFR1, FGFR3, and FGFR4. In some embodiments, compounds of the present invention are more than 50-fold selective over FGFR1, FGFR3, and FGFR4. In some embodiments, compounds of the present invention are more than 100-fold selective over FGFR1, FGFR3, and FGFR4. In some embodiments, compounds of the present invention are more than 200-fold selective over FGFR1, FGFR3, and FGFR4.

[0257] The term "biological sample," as used herein, includes, but is not limited to, a cell culture or extract thereof; a biopsy or extract thereof obtained from a mammal; and blood, saliva, urine, feces, semen, tears, or other bodily fluids or extracts thereof.

[0258] Inhibition of the activity of FGFR2 or its variants in biological samples is useful for a variety of purposes known to those skilled in the art, including but not limited to blood transfusion, organ transplantation, biological specimen preservation, and biological assays.

[0259] Another embodiment of the invention relates to a method of inhibiting protein kinase activity in a patient, comprising administering to said patient a compound of the invention, or a composition comprising said compound.

[0260] According to another embodiment, the present invention relates to a method for inhibiting the activity of FGFR2 or a mutant thereof in a patient, comprising administering to the patient a compound of the present invention or a composition containing the compound. According to certain embodiments, the present invention relates to a method for reversibly or irreversibly inhibiting the activity of FGFR2 or one or more mutants thereof in a patient, comprising administering to the patient a compound of the present invention or a composition containing the compound. In some embodiments, the present invention relates to a method for reversibly inhibiting the activity of FGFR2 or one or more mutants thereof in a patient, comprising administering to the patient a compound of the present invention or a composition containing the compound. In some embodiments, the present invention relates to a method for irreversibly inhibiting the activity of FGFR2 or one or more mutants thereof in a patient, comprising administering to the patient a compound of the present invention or a composition containing the compound.

[0261] In some embodiments, the present invention relates to a method of irreversibly inhibiting the activity of one or more of FGFR2, or mutants thereof, in a patient, comprising administering to the patient a compound of the present invention, or a composition containing the compound, wherein the compound forms a covalent bond with FGFR2, or mutants thereof. In some embodiments, the present invention relates to a method of irreversibly inhibiting the activity of one or more of FGFR2, or mutants thereof, in a patient, comprising administering to the patient a compound of the present invention, or a composition containing the compound, wherein the compound forms a covalent bond with FGFR2, or mutants thereof. W and a cysteine ​​of FGFR2 or a mutant thereof. In some embodiments, the present invention relates to a method of irreversibly inhibiting the activity of one or more of FGFR2, or mutants thereof, in a patient, comprising administering to the patient a compound of the present invention, or a composition containing the compound, wherein the compound is present at a position corresponding to the R W and forms a covalent bond with Cys491 of FGFR2 or its mutant.

[0262] According to another embodiment, the present invention provides a method for treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof. Such disorders are described in detail herein. In some embodiments, the present invention provides a method for treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound reversibly inhibits FGFR2 or a mutant thereof.

[0263] In some embodiments, the present invention provides a method of treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, which irreversibly inhibits FGFR2 or a mutant thereof. In some embodiments, the present invention provides a method of treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound forms a covalent bond with FGFR2 or a mutant thereof. In some embodiments, the present invention provides a method of treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, the method comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound is a nucleotide analog of the R W and a cysteine ​​of FGFR2 or a mutant thereof. In some embodiments, the present invention provides a method of treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound is W and forms a covalent bond with Cys491 of FGFR2 or its mutant.

[0264] According to another embodiment, the present invention provides a method of inhibiting signaling activity of FGFR2, or a mutant thereof, in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to the present invention, or a pharmaceutically acceptable composition thereof. In some embodiments, the present invention provides a method of inhibiting FGFR2 signaling activity in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to the present invention, or a pharmaceutically acceptable composition thereof.

[0265] In some embodiments, the present invention provides a method of treating a disorder mediated by FGFR2 or a mutant thereof in a patient in need thereof, comprising administering to the patient a compound according to the present invention or a pharmaceutically acceptable composition thereof, wherein the compound reversibly inhibits FGFR2 or a mutant thereof.

[0266] The compounds described herein can also inhibit FGFR2 function by incorporating them into agents that catalyze the destruction of FGFR2. For example, these compounds can be incorporated into proteolysis-targeting chimeric proteins (PROTACs). PROTACs are bifunctional molecules, with one moiety capable of engaging an E3 ubiquitin ligase and the other moiety capable of binding to a target protein destined for degradation by the cell's protein quality control machinery. Recruitment of the target protein to a specific E3 ligase results in its tagging for destruction (i.e., ubiquitination) and subsequent degradation by the proteasome. Any E3 ligase can be used. The part of the PROTAC that engages the E3 ligase is linked to the part of the PROTAC that engages the target protein via a linker consisting of a variable chain of atoms. Thus, recruitment of FGFR2 to the E3 ligase results in the destruction of the FGFR2 protein. This variable chain of atoms can include, for example, a ring, heteroatoms, and / or repeating polymer units. It can be rigid or flexible and can be attached to the two moieties using techniques that are standard in the field of organic synthesis. Combination therapy

[0267] Depending on the particular disorder, condition, or disease to be treated, additional therapeutic agents that are normally administered to treat that condition may be administered in combination with the compounds and compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat a particular disease or condition are known as "appropriate for the disease, or condition, being treated."

[0268] Thus, in certain embodiments, methods of treatment involve administering a compound or composition of the invention in combination with one or more additional therapeutic agents, hi certain other embodiments, methods of treatment involve administering a compound or composition of the invention as the only therapeutic agent.

[0269] In some embodiments, the one or more additional therapeutic agents are selected from an antibody, an antibody-drug conjugate, a kinase inhibitor, an immunomodulatory agent, and a histone deacetylase inhibitor. In some embodiments, the one or more additional therapeutic agents are selected from the following agents, or pharmaceutically acceptable salts thereof: BCR-ABL inhibitors: e.g., imatinib, inilotinib, nilotinib, dasatinib, bosutinib, ponatinib, bafetinib, danusertib, saracatinib, PF03814735; ALK inhibitors (see Dardaei et al., 2018, Nat Med.; 24(4):512-517): e.g., crizotinib, NVP-TAE684, ceritinib, alectinib, brigatinib, entrecinib, lorlatinib; BRAF inhibitors (Prahallad et al., 2015, Cell Rep. 12, 1978-1985): e.g., vemurafenib, dabrafenib; FGFR inhibitors: e.g., infigratinib, dovitinib, erdafitinib, BLU-554, AZD4547; FLT3 inhibitors: e.g., sunitinib, midostaurin, tanutinib, sorafenib, lestaurtinib, quizartinib, and crenolanib; MEK inhibitors (Fedele et al., 2018, BioRxiv 307876; Torres-Ayuso et al, 2018, Cancer Discov. 8, 1210-1212; and Wong et al, 2016, Oncotarget. 2016 Oct 4;7(40):65676-65695): e.g., trametinib, cobimetinib, binimetinib, selumetinib; ERK inhibitors: e.g., ulixertinib, MK-8353, LY-3214996; VEGF receptor inhibitors: e.g., bevacizumab, axitinib, aflibercept, brivanib, motesanib, pasireotide, sorafenib; tyrosine kinase inhibitors: e.g., thiazol-1,3-dimethyl-2-propanol (THC1), ... EGFR inhibitors: e.g., erlotinib, linifanib, sunitinib, pazopanib; epidermal growth factor receptor (EGFR) inhibitors: gefitinib, osimertinib, cetuximab, panitumumab; HER2 receptor inhibitors: e.g., trastuzumab, neratinib, lapatinib; MET inhibitors: e.g., crizotinib, cabozantinib; CD20 antibodies: e.g., rituximab, toxinib tositumomab, ofatumumab; DNA synthesis inhibitors: for example, capecitabine, gemcitabine, nelarabine, hydroxycarbamide; antitumor agents: for example, oxaliplatin, cisplatin; HER dimerization inhibitors: for example, pertuzumab; human granulocyte colony-stimulating factor (G-CSF) modulators: for example, filgrastim; immunomodulatory agents: for example, afutuzumab, lenalidomide, thalidomide, pomalidomide; CD40 inhibitors: for example , dacetuzumab; pro-apoptotic receptor agonists (PARA): for example, dulanermin; heat shock protein (HSP) inhibitors: for example, tanespimycin (17-allylamino-17-desmethoxygeldanamycin); hedgehog antagonists: for example, vismodegib; proteasome inhibitors: for example, bortezomib;PI3K inhibitors: for example, pictilisib, dactolisib, buparlisib, taselisib, idelalisib, duvelisib, umbralisib; phospholipase A2 inhibitors: for example, anagrelide; BCL-2 inhibitors: for example, venetoclax; aromatase inhibitors: exemestane, letrozole, anastrozole, faslodex, tamoxifen; topoisomerase inhibitors: topoisomerase I inhibitors: for example, irinotecan, topotecan; topoisomerase II inhibitors: for example, etoposide, teniposide; mTOR inhibitors: for example, temsirolimus, ridaforolimus, everolimus, sirolimus; osteoclast bone resorption inhibitors: for example, zoledronic acid; CD33 antibody-drug conjugates: for example, gemtuzumab ozogamicin; CD22 antibody-drug conjugates: for example, inotuzumab ozogamicin; CD20 antibody-drug conjugates: for example, ibritumomab tiuxetan; somatostatin analogs: for example, octreotide; interleukins Interleukin-11 (IL-11): e.g., oprelvekin; synthetic erythropoietin: e.g., darbepoetin alfa; receptor activator of nuclear factor kappa B (RANK) inhibitor: e.g., denosumab; thrombopoietin mimetic peptides: e.g., romiplostim; cell growth stimulating factors: e.g., palifermin; anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies: e.g., figitumumab; anti-CS1 antibodies: e.g., elotuzumab; CD52 antibodies: e.g., alemtuzumab; CTLA-4 inhibitors: for example, tremelimumab, ipilimumab; PD1 inhibitors: for example, nivolumab, pembrolizumab; immunoadhesins; for example, pidilizumab, AMP-224; PDL1 inhibitors: for example, MSB0010718C; YW243.55.S70, MPDL3280A; MEDI-4736, MSB-0010718C, or MDX-1105; LAG-3 inhibitors: for example, BMS-986016; GITR agonists; GITR fusion proteins and anti-GITR antibodies;Histone deacetylase inhibitors (HDIs): e.g., voninostat; anti-CTLA4 antibodies: e.g., tremelimumab, ipilimumab; alkylating agents: e.g., temozolomide, dactinomycin, melphalan, altretamine, carmustine, bendamustine, busulfan, carboplatin, lomustine, cisplatin, chlorambucil, cyclophosphamide, dacarbazine, altretamine, ifosfamide, procarbazine, mechlorethamine, mustine, and mechloroethamine, streptozocin, thiotepa; biological response modifiers: e.g., bacillus Calmette-Guerin, denileukin diftitox; antitumor antibiotics: e.g., doxorubicin, bleomycin, dacarbazine ... unorubicin, daunorubicin liposomal, mitoxantrone, epirubicin, idarubicin, mitomycin C; microtubule inhibitors: e.g., estramustine; cathepsin K inhibitors: e.g., odanacatib; epothilone analogs: e.g., ixabepilone; TpoR agonists: e.g., eltrombopag; antimitotics: e.g., docetaxel; corticosteroid inhibitors: e.g., aminoglutethimide; antiandrogens: androgen receptor inhibitors: for example, enzalutamide, abiraterone acetate, orteronel, galeterone, and seviteronel, bicalutamide, flutamide; androgens: for example, fluoxymesterone; CDK1 inhibitors: for example, alvocidib, palbociclib, ribociclib, trilaciclib , abemaciclib; gonadotropin-releasing hormone (GnRH) receptor agonists: for example, leuprolide or leuprolide acetate; taxane antitumor agents: for example, cabazitaxel, larotaxel; 5-HT1a receptor agonists: for example, xaliproden; HPV vaccines: for example, Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck;Iron chelators: e.g., deferasirox; antimetabolites: e.g., claribine, 5-fluorouracil, 6-thioguanine, pemetrexed, cytarabine, cytarabine liposomes, decitabine, hydroxyurea, fludarabine, floxuridine, cladribine, methotrexate, pentostatin; bisphosphonates: e.g., pamidronate; demethylating agents: e.g., 5-azacytidine, decitabine; antitumor plant alkaloids: e.g., protein-bound paclitaxel; vinblastine, vincristine, vinorelbine, paclitaxel; retinoids: e.g., alitretinoin, tretinoin, isotretinoin, bexarotene; glucocorticosteroids: e.g., hydrocortisone, dexamethasone, prednisolone solone, prednisone, methylprednisolone; cytokines: e.g., interleukin-2, interleukin-11 (oprevelkin), alpha interferon alpha (IFN-α); estrogen receptor downregulators: fulvestrant; antiestrogens: e.g., tamoxifen, toremifene; selective estrogen receptor modulators (SERMs): e.g., raloxifene; luteinizing hormone-releasing hormone (LHRH) agonists: e.g., goserelin; progesterones: e.g., megestrol; cytotoxic agents: arsenic trioxide, asparaginase (L-asparaginase, also known as Erwinia L-asparaginase); anti-nausea drugs: e.g., NK-1 receptor antagonists (e.g., casopitant); cytoprotective agents: e.g., amifostine, leucovorin;and immune checkpoint inhibitors. The term "immune checkpoint" refers to a group of molecules on the cell surface of CD4 and CD8 T cells. Immune checkpoint molecules include, but are not limited to, programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40, and LAG3. Immunotherapeutic agents that may act as immune checkpoint inhibitors useful in the methods of the present disclosure include, but are not limited to, inhibitors of PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and / or TGFRβ.

[0270] In some embodiments, the one or more additional therapeutic agents are selected from the following agents: anti-FGFR antibodies; cytotoxic agents; estrogen receptor-targeted or other endocrine therapies, immune checkpoint inhibitors, CDK inhibitors, other receptor tyrosine kinase inhibitors, BRAF inhibitors, MEK inhibitors, PI3K inhibitors, SHP2 inhibitors, and SRC inhibitors (see M. Katoh, Nat. Rev. Clin. Oncol. 2019, 16:105-122; Y. K. Chae, et al. Oncotarget 2017, 8:16052-16074; L. Formisano et al., Nat. Comm. 2019, 10:1373-1386; and references incorporated herein).

[0271] The structures of active compounds identified by code number, generic name or trade name can be obtained from the current edition of the standard compendium "The Merck Index" or from databases such as Patents International (e.g. IMS World Publications).

[0272] The compounds of the present invention can also be used in combination with known therapeutic processes, such as the administration of hormones or radiation. In certain embodiments, provided compounds are used as radiosensitizers, particularly for the treatment of tumors that exhibit poor sensitivity to radiation therapy.

[0273] The compound of the present invention can be administered alone or in combination with one or more other therapeutic compounds, and possible combined therapy can be in the form of a fixed combination, or the compound of the present invention and one or more other therapeutic compounds are administered alternately or independently, or in the form of a fixed combination administered in combination with one or more other therapeutic compounds.Otherwise or in addition, the compound of the present invention can be administered in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination thereof, particularly for tumor treatment.As described above, in the context of other treatment strategies, long-term treatment is possible, as well as adjuvant treatment.Other possible treatments are treatments to maintain the patient's condition after tumor regression, or even chemopreventive treatment, for example, in patients at risk.

[0274] These additional agents can be administered separately from the compound-containing compositions of this invention, as part of a multiple dose regimen. Alternatively, these agents can be part of a single dosage form, mixed together with the compound of this invention in a single composition. When administered as part of a multiple dose regimen, the two active agents may be given simultaneously, sequentially, or within a period of each other, usually within 5 hours of each other.

[0275] As used herein, the terms "combination," "combined," and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the present invention. For example, a compound of the present invention can be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms, or together in a single unit dosage form. Thus, the present invention provides a single unit dosage form comprising a compound of the present invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0276] The amounts of both the compounds of the present invention and additional therapeutic agents (in compositions containing such additional therapeutic agents) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, the compositions of this invention should be formulated so that a dosage of between 0.01-100 mg / kg of body weight per day of the compound of the present invention can be administered.

[0277] In these compositions containing an additional therapeutic agent, the additional therapeutic agent and the compound of the present invention may act synergistically. Therefore, the amount of the additional therapeutic agent in such compositions is less than the amount required in a monotherapy utilizing only that therapeutic agent. In such compositions, the additional therapeutic agent can be administered at a dosage of between 0.01 and 1,000 μg per kg of body weight per day.

[0278] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably, the amount of additional therapeutic agent in the compositions of the present disclosure will range from about 50% to 100% of the amount that would normally be present in a composition comprising that agent as the only therapeutically active agent.

[0279] The compounds of the present invention, or pharmaceutical compositions thereof, can also be incorporated into compositions for coating implantable medical devices, such as prostheses, artificial valves, vascular grafts, stents and catheters.For example, vascular stents are used to overcome restenosis (re-narrowing of the blood vessel wall after injury).However, patients who use stents or other implantable devices are at risk of blood clot formation or platelet activation.These undesirable effects can be prevented or reduced by pre-coating the device with a pharmaceutically acceptable composition containing a kinase inhibitor.An implantable device coated with the compounds of the present invention is another embodiment of the present invention.

[0280] Any of the compounds and / or compositions of the present disclosure can be provided in a kit containing these compounds and / or compositions. Thus, in some embodiments, the compounds and / or compositions of the present disclosure are provided in a kit.

[0281] The present disclosure is further described by the following non-limiting examples. [Example]

[0282] Examples are provided herein to facilitate a more complete understanding of the present disclosure. The following examples serve to illustrate exemplary methods of making and practicing the subject matter of the present disclosure. However, the scope of the present disclosure should not be construed as being limited to the specific embodiments disclosed in these examples, which are merely illustrative.

[0283] As shown in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures: While the general methods illustrate the synthesis of certain compounds of the invention, it is understood that the following general methods, and other methods known to those of skill in the art, can be applied to other classes and subclasses and species of each of these compounds as described herein.

[0284] In the description of synthetic methods set forth below, it should be understood that all reaction conditions (e.g., reaction solvents, pressures, temperatures, durations, and work-up procedures) are selected from standard conditions for the reaction unless otherwise indicated. In the general schemes, it will be understood by those skilled in the art of organic synthesis that functional groups present on various portions of the molecules should be compatible with the reactants and reactions proposed. Substituents that are not compatible with the reaction conditions will be apparent to those skilled in the art, and alternative methods (e.g., use of protecting groups or alternative reactions) are indicated accordingly. Starting materials for these examples are either commercially available or readily prepared by standard methods from known materials.

[0285] It is contemplated that at least some of the compounds identified herein as "intermediates" are compounds of the present disclosure.

[0286] In some embodiments, compounds of Formula I are prepared according to the general procedure illustrated in Scheme 1 below. Scheme 1 [ka]

[0287] In some embodiments, step 1 comprises reacting Int-1 with a compound of formula XR 7 with a compound of formula (I), whereby R 7 is as defined in embodiments herein and X is a leaving group to form a compound of formula Int-2.

[0288] In some embodiments, step 2 involves iodination of a compound of formula Int-2. In some embodiments, the reagent used is N-iodosuccinimide.

[0289] In some embodiments, step 3 comprises reacting a compound of formula Int-3 with a Cy functionalized with a suitable reactive group. 6 -L 6 -R W to form a compound of formula Int-4. In some embodiments, the suitable reactive group is a boronic ester. In some embodiments, the suitable reactive group is a pinacol boronic ester.

[0290] In some embodiments, step 4 comprises reacting a compound of formula Int-4 with an R 5 to form a compound of Formula I. In some embodiments, the suitable reactive group is a boronic acid or boronic ester. Example 1 N-(4-(4-amino-5-(3-methoxy-4-(pyrimidin-2-yloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka] 5-Bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0291] Step 1: A round-bottom flask was charged with 5-bromo-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3 g, 14.0 mmol), CsCO (9.10 g, 28.0 mmol), DMF (50 mL), and a stir bar. The mixture was cooled to 0 °C, and iodomethane (1.98 g, 14.0 mmol) was added. The solution was stirred at 0 °C for 3 h. The reaction mixture was diluted with HO (300 mL), and the aqueous phase was extracted three times with EA (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material obtained was purified by silica gel chromatography (eluted with MeOH / DCM = 1 / 80). Concentration in vacuo gave 5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (2.20 g, 70%) as a yellow crystalline solid. 5-Bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0292] Step 2: A round-bottom flask was charged with 5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3 g, 13.2 mmol), TFA (7.52 g, 66.0 mmol), DCM (50 mL), and a stir bar. The mixture was cooled to 0 °C, and 1-iodopyrrolidine-2,5-dione (2.96 g, 13.2 mmol) was added. The solution was stirred at room temperature for 2 h. The reaction mixture was diluted with saturated Na2SO3 solution (100 mL). The pH of the solution was adjusted to 7-8 with saturated NaHCO3 solution. The solid was filtered and washed with HO, followed by a small amount of DCM to give 5-bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3.70 g, 80%) as a white amorphous solid. N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka]

[0293] Step 3: A resealable reaction vial was charged with 5-bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3.7 g, 10.51 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide (3.7 g, 12.61 mmol), Pd(PPh3)4 (1.21 g, 1.05 mmol), K3PO4 (6.68 g, 31.53 mmol), DMF (50 mL), HO (3 mL), and a stir bar, then evacuated and purged with nitrogen three times. The mixture was stirred at 50 °C for 1 h. The reaction mixture was concentrated in vacuo. The resulting crude material was purified by silica gel chromatography (eluting with MeOH / DCM = 1 / 100 to 1 / 20). Concentration in vacuo gave N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide (2.2 g, 54%) as an off-white amorphous solid. N-(4-(4-amino-5-(3-methoxy-4-(pyrimidin-2-yloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka]

[0294] Step 4: A resealable reaction vial was charged with N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide (120 mg, 0.31 mmol), 2-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrimidine (122 mg, 0.373 mmol), Pd(DtBPF)Cl (20.1 mg, 0.031 mmol), CsF (240 mg, 0.930 mmol), DMF (4 mL), HO (0.5 mL), and a stir bar, then evacuated and purged with nitrogen three times. The mixture was stirred at 90 °C for 2 hours. The reaction mixture was concentrated in vacuo. The resulting crude material was purified by TLC (eluted with MeOH / DCM=1 / 15) and concentrated in vacuo to give N-(4-(4-amino-5-(3-methoxy-4-(pyrimidin-2-yloxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide (13.9 mg, 9%) as a white amorphous solid. Example 2 An alternative route to N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka] 6-(4-aminophenyl)-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0295] Step 1: A round-bottom flask was charged with tert-butyl-4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenylcarbamate (20 g, 47.8 mmol), DCM (240 mL), and a stir bar. TFA (60 mL) was added. The solution was stirred at room temperature for 4 hours. The reaction mixture was made basic with saturated aqueous NaCO solution (40 mL), and the solid was filtered and concentrated in vacuo. This afforded 6-(4-aminophenyl)-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (14 g, 92.1%) as an off-white amorphous solid. N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka]

[0296] Step 2: A resealable reaction vial was charged with 6-(4-aminophenyl)-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (10.0 g, 31.4 mmol), DMF / pyridine (4:1, 200 mL), and a stir bar, then evacuated and purged with nitrogen three times. The solution was then cooled to 0 °C. Methacryloyl chloride (4.0 g, 37.7 mmol) was then dissolved in DMF (10 mL) and added to the solution, and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with HO (200 mL), and the aqueous phase was extracted three times with ethyl acetate (200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was recrystallized from MeCN. Concentration in vacuo gave N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide (8.8 g, 73%) as an off-white amorphous solid. Example 3 4-(4-amino-6-(4-methacrylamidophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-(oxetan-2-ylmethyl)benzamide [ka] Methyl 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzoate [ka]

[0297] Step 1: A resealable reaction vial was charged with 5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (20 g, 72.9 mmol), [4-(methoxycarbonyl)phenyl]boronic acid (15.7 g, 87.4 mmol), Pd(DtBPF)Cl (4.74 g, 7.29 mmol), CsF (33.1 g, 218 mmol), DMF (200 mL), HO (25 mL), and a stir bar, then evacuated and purged with nitrogen three times. The mixture was stirred at 90 °C for 1 h. The reaction mixture was diluted with HO (500 mL), and the aqueous phase was extracted three times with DCM (200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The reaction mixture was added with MeCN (10 mL) and filtered through a pad of Celite®, which was washed with MeCN. The filtrate was concentrated in vacuo to give a solid, which was methyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoate (11.0 g, 38.9 mmol), obtained as a yellow amorphous solid. Methyl 4-(4-amino-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzoate [ka]

[0298] Step 2: A round-bottom flask was charged with methyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoate (10.9 g, 38.6 mmol), DCM (200 mL), TFA (13.1 g, 115 mmol), and a stir bar. The mixture was cooled to 0 °C, NIS (9.53 g, 42.4 mmol) was added, and the solution was stirred at room temperature for 1 h. The reaction mixture was diluted with NaSO solution, and the aqueous phase was extracted three times with DCM (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. DCM (20 mL) was added, and the reaction mixture was filtered through a pad of Celite®, washing the pad with a small amount of DCM. The filtrate was concentrated in vacuo and the resulting solid was methyl 4-{4-amino-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoate (12.0 g, 29.3 mmol) obtained as an off-white amorphous solid. Methyl 4-(4-amino-6-(4-methacrylamidophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzoate [ka]

[0299] Step 3: A resealable reaction vial was charged with methyl 4-{4-amino-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoate (11.9 g, 29.1 mmol), 2-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (10.0 g, 34.9 mmol), Pd(dppf)Cl (2.12 g, 2.91 mmol), KPO (18.5 g, 87.3 mmol), DMF (100 mL), HO (12.5 mL), and a stir bar, which was then evacuated and purged with nitrogen three times. The mixture was stirred at 90 °C for 1 hour. The reaction mixture was diluted with HO (500 mL), and the aqueous phase was extracted three times with DCM (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography (eluted with MeOH / DCM = 1 / 40). Concentration in vacuo afforded methyl 4-{4-amino-7-methyl-6-[4-(2-methylprop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoate (7.70 g, 17.4 mmol) as a yellow amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzoic acid [ka]

[0300] Step 4: A round-bottom flask was charged with methyl 4-{4-amino-7-methyl-6-[4-(2-methylprop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoate (7.65 g, 17.3 mmol), MeOH (40 mL), NaOH (2 N, 40 mL), and a stir bar. The solution was stirred at room temperature overnight. The pH of the resulting mixture was adjusted to 6-7 with HCl (2 M). The reaction mixture was filtered through a pad of Celite®, and the pad was washed with HO. The filtrate was concentrated in vacuo to give a solid, 4-{4-amino-7-methyl-6-[4-(2-methylprop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoic acid (6.50 g, 15.2 mmol), which was obtained as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-(oxetan-2-ylmethyl)benzamide [ka]

[0301] Step 5: A round-bottom flask was charged with 4-{4-amino-7-methyl-6-[4-(2-methylprop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoic acid (60 mg, 0.14 mmol), 1-(oxetan-2-yl)methanamine (13.4 mg, 0.15 mmol), HATU (58.7 mg, 0.15 mmol), DIEA (54.2 mg, 0.42 mmol), and a stir bar. Dimethylformamide (3 mL) was added, and the solution was stirred at 25° C. for 2 hours. The resulting crude material was purified by HPLC (Column: XBridge Prep Phenyl OBD Column, 19 × 150 mm, 5 μm, 13 nm). Lyophilization afforded 4-{4-amino-7-methyl-6-[4-(2-methylprop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-N-[(oxetan-2-yl)methyl]benzamide (20.0 mg, 0.040 mmol) as an off-white amorphous solid.

[0302] Additional compounds prepared according to the methods of Examples 1-3 are illustrated in Table 2 below. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10] [Table 2-11] [Table 2-12] [Table 2-13] [Table 2-14] [Table 2-15] [Table 2-16]

Table 2-17

Table 2-18

Table 2-19

Table 2-20

Table 2-21

Table 2-22

Table 2-23

Table 2-24

Table 2-25

Table 2-26

Table 2-27

Table 2-28

Table 2-29

Table 2-30

Table 2-31

Table 2-32

Table 2-33

Table 2-34

Table 2-35

Table 2-36

Table 2-37

Table 2-38

Table 2-39

Table 2-40

Table 2-41

Table 2-42

Table 2-43

Table 2-44

Table 2-45

Table 2-46

Table 2-47

Table 2-48

Table 2-49

Table 2-50

Table 2-51

Table 2-52

Table 2-53

Table 2-54

Table 2-55

Table 2-56

Table 2-57

Table 2-58

Table 2-59

Table 2-60

Table 2-61

Table 2-62

Table 2-63

Table 2-64

Table 2-65

Table 2-66

Table 2-67

Table 2-68

Table 2-69

Table 2-70

Table 2-71

Table 2-72

Table 2-73

Table 2-74

Table 2-75

Table 2-76

Table 2-77

Table 2-78

Table 2-79

Table 2-80

Table 2-81

Table 2-82

Table 2-83

Table 2-84

Table 2-85

Table 2-86

Table 2-87

Table 2-88

Table 2-89

Table 2-90

Table 2-91

Table 2-92

Table 2-93

Table 2-94

Table 2-95

Table 2-96

Table 2-97

Table 2-98

Table 2-99

Table 2-100

Table 2-101

Table 2-102

Table 2-103

Table 2-104

Table 2-105

Table 2-106

Table 2-107

Table 2-108

Table 2-109

Table 2-110

Table 2-111

Table 2-112

Table 2-113

Table 2-114

Table 2-115

Table 2-116

Table 2-117

Table 2-118

Table 2-119

Table 2-120

Table 2-121

Table 2-122

Table 2-123

Table 2-124

Table 2-125

Table 2-126

Table 2-127

Table 2-128

Table 2-129

Table 2-130

Table 2-131

Table 2-132

Table 2-133

Table 2-134

[0303] Step 1: A round-bottom flask was charged with N-(4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}phenyl)prop-2-enamide (200 mg, 537 μmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (199 mg, 644 μmol), Pd(dtbpf)Cl (34.9 mg, 53.7 μmol), KPO (341 mg, 1.61 mmol), 5 mL of DMF, and a stir bar. The solution was stirred at 90° C. for 2 hours. The reaction mixture was diluted with water (50 mL), and the aqueous phase was extracted three times with dichloromethane (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by silica gel chromatography (2 g column; eluted with heptane / ethyl acetate; 3:1). Concentration in vacuo afforded tert-butyl 4-{4-amino-7-methyl-6-[4-(prop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate (121 mg, 48%) as a yellow oil. N-(4-(4-amino-7-methyl-5-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)acrylamide [ka]

[0304] Step 2: A round-bottom flask was charged with tert-butyl 4-{4-amino-7-methyl-6-[4-(prop-2-enamido)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate (30 mg, 63.2 μmol), 0.2 mL of TFA, 0.8 mL of DCM, and a stir bar. The solution was stirred at room temperature for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure. The crude material obtained was purified by HPLC (acetonitrile / water / 0.1% formic acid). Lyophilization gave N-{4-[4-amino-7-methyl-5-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide (16.8 mg, 71%) as a white amorphous solid. N-(4-(4-amino-7-methyl-5-(1-(2,2,2-trifluoroacetyl)-1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)acrylamide [ka]

[0305] Step 3: A round-bottom flask was charged with N-{4-[4-amino-7-methyl-5-(1,2,3,6-tetrahydropyridin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide (40 mg, 106 μmol), TEA (32.1 mg, 318 μmol), DMAP (1.29 mg, 10.6 μmol), 5 mL of DCM, and a stir bar. TFAA was added dropwise at 0° C. The solution was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (30 mL), and the aqueous phase was extracted three times with dichloromethane (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude material was purified by HPLC (acetonitrile / water / 0.1% formic acid). Lyophilization afforded N-(4-{4-amino-7-methyl-5-[1-(2,2,2-trifluoroacetyl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}phenyl)prop-2-enamide (27.9 mg, 37%) as a white amorphous solid.

[0306] Additional compounds prepared according to the method of Example 4 are illustrated in Table 3 below. [Table 3] Scheme 3 [ka] Example 5 N-(4-(4-amino-7-methyl-5-(1-(pyrrolidine-1-carbonyl)piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka] tert-Butyl 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate [ka]

[0307] Step 1: A round-bottom flask was charged with 5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3.00 g, 10.9 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine-1-carboxylate (4.01 g, 13.0 mmol), Pd(dtbpf)Cl (710 mg, 1.09 mmol), KPO (6.91 g, 32.6 mmol), and a stir bar. DMF (45 mL) and HO (3 mL) were added, and the solution was stirred at 90 °C for 3 h. The mixture was diluted with EtOAc (300 mL) and washed with water (3×100 mL), the organic phase was concentrated, and the crude product was purified on a silica gel column with DCM:MeOH=25:1 to give tert-butyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate (2.97 g, 83%) as a brown oil. tert-Butyl 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate [ka]

[0308] Step 2: A round-bottom flask was charged with tert-butyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}-1,2,3,6-tetrahydropyridine-1-carboxylate (1.70 g, 5.16 mmol), Pd / C (326 mg, 154 μmol), and a stir bar. MeOH (50 mL) was added, and the solution was stirred under H at 50° C. for 48 h. The mixture was filtered and washed five times with MeOH, and the filtrate was concentrated to give tert-butyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}piperidine-1-carboxylate (900 mg, 53%) as a brown oil. tert-Butyl 4-(4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate [ka]

[0309] Step 3: A round-bottom flask was charged with tert-butyl 4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}piperidine-1-carboxylate (800 mg, 2.41 mmol), NBS (428 mg, 2.41 mmol), and a stir bar. ACN (20 mL) was added, and the solution was stirred at 25° C. for 0.5 hours. The mixture was concentrated under reduced pressure to give the product, tert-butyl 4-{4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}piperidine-1-carboxylate (500 mg, 51%), as a brown solid. This crude product was used in the next step without further purification. 6-Bromo-7-methyl-5-(piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0310] Step 4: A round-bottom flask was charged with tert-butyl 4-{4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl}piperidine-1-carboxylate (500 mg, 1.21 mmol), DCM (5 mL), and a stir bar. TFA (0.5 mL) was added, and the solution was stirred at 25° C. for 2 hours. The mixture was concentrated under reduced pressure and diluted with DCM (30 mL), washed with saturated aqueous NaHCO (3×15 mL), and the organic phase was concentrated to give the product, 6-bromo-7-methyl-5-(piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (310 mg, 83%), as a brown oil. (4-(4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidin-1-yl)(pyrrolidin-1-yl)methanone [ka]

[0311] Step 5: A round-bottom flask was charged with 6-bromo-7-methyl-5-(piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (280 mg, 902 μmol), DIEA (580 mg, 4.50 mmol), DCM (10 mL), and a stir bar. Triphosgene (106 mg, 360 μmol) was added, and the solution was stirred at room temperature for 1 hour. Then pyrrolidine (512 mg, 7.21 mmol) was added, and the solution was stirred at room temperature for 1 hour. The solvent was removed, and the crude product was purified by C18 flash to give 6-bromo-7-methyl-5-[1-(pyrrolidine-1-carbonyl)piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (160 mg, 21%) as an off-white solid. N-(4-(4-amino-7-methyl-5-(1-(pyrrolidine-1-carbonyl)piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide [ka]

[0312] Step 6: A resealable reaction vial was charged with 6-bromo-7-methyl-5-[1-(pyrrolidine-1-carbonyl)piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (140 mg, 0.34 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (112 mg, 0.41 mmol), Pd(dppf)Cl (25.1 mg, 34.3 μmol), KPO (216 mg, 1.02 mmol), and a stir bar, and then evacuated and purged with nitrogen three times. DMF (1 mL) and HO (0.1 mL) were added, and the mixture was stirred at 90 °C for 3 hours. The resulting mixture was purified by passing through a C18 column. The resulting crude material was purified by HPLC. Lyophilization afforded N-(4-{4-amino-7-methyl-5-[1-(pyrrolidine-1-carbonyl)piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}phenyl)-2-methylprop-2-enamide (24.3 mg, 15%) as a white amorphous solid.

[0313] Additional compounds prepared according to the method of Example 5 are illustrated in Table 4 below. [Table 4] Scheme 4 [ka] Example 6 N-(4-(4-amino-7-methyl-5-(1-methylpiperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)acrylamide [ka] tert-Butyl 4-(6-(4-acrylamidophenyl)-4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate [ka]

[0314] Step 1: A round-bottom flask was charged with tert-butyl 4-(4-amino-6-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate (700 mg, 1.7 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (559 mg, 2.0 mmol), Pd(dtbpf)Cl (124 mg, 0.17 mmol), KPO (1.08 g, 5.1 mmol), and a stir bar. DMF (10 mL) and HO (1 mL) were added, and the solution was stirred at 90 °C for 3 h. The mixture was diluted with EtOAc (100 mL) and washed with water (3 x 100 mL), the organic phase was concentrated, and the crude product was purified by silica gel column with DCM:MeOH = 25:1 to give tert-butyl 4-(6-(4-acrylamidophenyl)-4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate (340 mg, 42%) as a yellow solid. tert-butyl 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate [ka]

[0315] Step 2: A round-bottom flask was charged with tert-butyl 4-(6-(4-acrylamidophenyl)-4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate (340 mg, 0.71 mmol), DCM (5 mL), and a stir bar. TFA (0.5 mL) was added, and the solution was stirred at 25° C. for 2 hours. The mixture was concentrated under reduced pressure and diluted with DCM (30 mL), washed with saturated aqueous NaHCO (3×15 mL), and the organic phase was concentrated to give the product, tert-butyl 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate (240 mg, 89%), as a brown oil. N-(4-(4-amino-7-methyl-5-(1-methylpiperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6yl)phenyl)acrylamide [ka]

[0316] Step 3: A round-bottom flask was charged with tert-butyl 4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)piperidine-1-carboxylate (120 mg, 0.32 mmol), NaBH(OAc) (81 mg, 0.38 mmol), (CHO) (20 mg, 0.64 mmol), and a stir bar. DCM (5 mL) and AcOH (0.5 mL) were added, and the solution was stirred at room temperature overnight. The reaction mixture was diluted with water (50 mL), and the aqueous phase was extracted three times with DCM (20 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by HPLC. Lyophilization gave N-(4-{4-amino-7-methyl-5-[1-(pyrrolidine-1-carbonyl)piperidin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}phenyl)-2-methylprop-2-enamide (8 mg, 6%) as a white amorphous solid.

[0317] Additional compounds prepared according to the method of Example 6 are illustrated in Table 5 below. [Table 5] Scheme 5 [ka] Example 7 N-(4-(4-amino-7-methyl-5-(1-((methylcarbamoyl)glycyl)piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)acrylamide [ka]

[0318] A resealable reaction vial was charged with N-{4-[4-amino-7-methyl-5-(piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide (100 mg, 0.265 mmol), 2-[(methylcarbamoyl)amino]acetic acid (35.0 mg, 0.265 mmol), HATU (121 mg, 0.32 mmol), DIEA (68.5 mg, 0.53 mmol), and a stir bar. Dimethylformamide (5 mL) was added, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (15 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by HPLC (acetonitrile / water / 0.1% formic acid). Lyophilization afforded N-{4-[4-amino-7-methyl-5-(1-{2-[(methylcarbamoyl)amino]acetyl}piperidin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl}prop-2-enamide (6.00 mg, 5%) as a white amorphous solid.

[0319] Additional compounds prepared according to the method of Example 7 are illustrated in Table 6 below. [Table 6] Example 8 Scheme 6 [ka] 5-(4-Methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0320] Step 1: A resealable reaction vial was charged with 5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (20 g, 72.9 mmol), (4-methoxyphenyl)boronic acid (13.3 g, 87.5 mmol), Pd(DtBPF)Cl (4.74 g, 7.29 mmol), CsF (33.1 g, 218 mmol), DMF (200 mL), HO (25 mL), and a stir bar, then evacuated and purged with nitrogen three times. The mixture was stirred at 90 °C for 1 h. The reaction mixture was diluted with HO (500 mL), and the aqueous phase was extracted three times with DCM (200 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The reaction mixture was added with MeCN (10 mL) and filtered through a pad of Celite®, which was washed with MeCN. The filtrate was concentrated in vacuo to give a solid, 5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (10.2 g, 55%), obtained as a yellow amorphous solid. 6-iodo-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0321] Step 2: A round-bottom flask was charged with 5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (9.8 g, 38.5 mmol), DCM (200 mL), TFA (13.1 g, 115 mmol), and a stir bar. The mixture was cooled to 0 °C, NIS (9.53 g, 42.4 mmol) was added, and the solution was stirred at room temperature for 1 h. The reaction mixture was diluted with NaSO solution, and the aqueous phase was extracted three times with DCM (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. DCM (20 mL) was added, and the reaction mixture was filtered through a pad of Celite®, washing the pad with a small amount of DCM. The filtrate was concentrated in vacuo to give a solid, 6-iodo-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (10.9 g, 74%), obtained as an off-white amorphous solid. tert-Butyl 4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate [ka]

[0322] Step 3: A resealable reaction vial was charged with 6-iodo-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1 g, 2.63 mmol), tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (1.2 g, 3.16 mmol), Pd(dppf)Cl (190 mg, 0.26 mmol), KPO (1.5 g, 6.9 mmol), DMF (20 mL), HO (2 mL), and a stir bar, which was then evacuated and purged with nitrogen three times. The mixture was stirred at 90° C. for 1 hour. The reaction mixture was diluted with HO (100 mL), and the aqueous phase was extracted three times with DCM (100 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography (eluted with MeOH / DCM = 1 / 40). Concentration in vacuo afforded tert-butyl 4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (800 mg, 61%) as a yellow solid. 5-(4-Methoxyphenyl)-7-methyl-6-(1(piperidin-4-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trifluoroacetate [ka]

[0323] Step 4: A round-bottom flask was charged with tert-butyl 4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (800 mg, 1.6 mmol), DCM (20 mL), and a stir bar. TFA (5 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed in vacuo to afford 5-(4-methoxyphenyl)-7-methyl-6-(1(piperidin-4-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trifluoroacetate (795 mg, 100%) as a dark oil. 1-(4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1H-pyrazol-1-yl)piperidin-1-yl)prop-2-en-1-one [ka]

[0324] Step 5: A round-bottom flask was charged with 5-(4-methoxyphenyl)-7-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine trifluoroacetate (120 mg, 0.24 mmol), EtN (72.9 mg, 0.72 mmol), DCM (10 mL), and a stir bar. The mixture was cooled to −30° C., prop-2-enoyl chloride (21.6 mg, 0.24 mmol) was added dropwise, and the solution was stirred at −30° C. for 0.5 h. The reaction mixture was quenched with MeOH and concentrated in vacuo. The resulting crude material was purified by prep-HPLC. Lyophilization afforded 1-(4-(4-(4-amino-5-(4-methoxyphenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-1H-pyrazol-1-yl)piperidin-1-yl)prop-2-en-1-one (33 mg, 30%) as a white amorphous solid.

[0325] Additional compounds prepared according to the method of Example 8 are illustrated in Table 7 below. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] [Table 7-8] [Table 7-9] [Table 7-10] [Table 7-11] [Table 7-12] [Table 7-13] [Table 7-14] [Table 7-15] [Table 7-16] [Table 7-17] [Table 7-18] [Table 7-19] Example 9 Scheme 7 [ka] N-(4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-6-yl)phenyl)methacrylamide [ka]

[0326] Step 1: A resealable reaction vial was charged with 6-bromopyrrolo[2,1-f][1,2,4]triazin-4-amine (500 mg, 2.34 mmol), 2-methyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (804 mg, 2.80 mmol), KPO (1.48 g, 7.02 mmol), Pd(dppf)Cl (171 mg, 234 μmol), and a stir bar, then evacuated and purged with nitrogen three times. DMF / HO (10 mL) was added, and the mixture was stirred at 90° C. for 1 hour. The reaction mixture was diluted with water (20 mL), and the aqueous phase was extracted three times with dichloromethane (20 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by prep-TLC (eluted with dichloromethane / methanol; 15:1). Concentration in vacuo afforded N-(4-{4-aminopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide (280 mg, 34%) as an off-white amorphous solid. N-(4-{4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide [ka]

[0327] Step 2: A round-bottom flask was charged with N-(4-{4-aminopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide (260 mg, 886 μmol), dimethylformamide (5 mL) was added, followed by NBS (313 mg, 1.77 mmol) at 0° C., and the solution was stirred at 0° C. for 1 h. The reaction mixture was diluted with NaSO(aq) (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material obtained was purified by prep-TLC (eluted with dichloromethane / methanol; 20:1). Concentration in vacuo afforded N-(4-{4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide (350 mg, 87%) as an orange amorphous solid. N-(4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-6-yl)phenyl)methacrylamide [ka]

[0328] Step 3: A resealable reaction vial was charged with N-(4-{4-amino-5,7-dibromopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide (300 mg, 665 μmol), tetrahydrofuran (6 mL) was added, and a stir bar was added, followed by evacuation and purging with nitrogen three times. At −78° C., n-BuLi (0.8 mL, 2 mmol) was added, and the mixture was stirred at −78° C. for 5 minutes. The reaction mixture was diluted with water (5 mL), and the aqueous phase was extracted three times with dichloromethane (5 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by TLC (eluted with dichloromethane / methanol; 15:1). Concentration in vacuo afforded N-(4-{4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide (100 mg, 40%) as an off-white amorphous solid. N-(4-(4-amino-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)phenyl)methacrylamide [ka]

[0329] Step 4: A resealable reaction vial was charged with N-(4-{4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-6-yl}phenyl)-2-methylprop-2-enamide (90.0 mg, 241 μmol), 2-methyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyridine (82.4 mg, 265 μmol), KPO (153 mg, 722 μmol), Pd(dppf)Cl (17.6 mg, 24.1 μmol), DMF / HO (4 mL), and a stir bar was added, followed by evacuation and purging with nitrogen three times, and the mixture was stirred at 90° C. for 1 hour. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by HPLC (Column: XBridge Prep OBD C18 column, 30 × 150 mm, 5 μm; Mobile Phase A: unspecified, Mobile Phase B: unspecified; Flow Rate: 60 mL / min; Gradient: 35B to 50B over 8 min; 220 nm; RT1: 7.54; RT2:; Injection Volume: ml; Run Number: ). Lyophilization afforded N-[4-(4-amino-5-{4-[(6-methylpyridin-2-yl)oxy]phenyl}pyrrolo[2,1-f][1,2,4]triazin-6-yl)phenyl]-2-methylprop-2-enamide (7.62 mg, 6%) as an off-white amorphous solid.

[0330] Additional compounds prepared according to the method of Example 9 are illustrated in Table 8 below. [Table 8-1] [Table 8-2] Example 10 Scheme 8. [ka] 4-(4-amino-7-(hydroxymethyl)-6-(4-methacrylamidophenyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka] 4-(4-amino-7-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka]

[0331] Step 1: A resealable reaction vial was charged with (4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)methanol (600 mg, 2.49 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide (983 mg, 2.99 mmol), Pd(dtbpf)Cl (162 mg, 249 μmol), CsF (1.14 g, 7.47 mmol), DMF:water=16:1 (8 mL), and a stir bar, then evacuated and purged with nitrogen three times. The solution was stirred at 90 °C for 2 h. The reaction mixture was quenched with water and extracted with DCM. The organic phase was separated and dried over Na SO , filtered, and concentrated in vacuo. The crude material was purified by prep-TLC and concentrated in vacuo to give 4-(4-amino-7-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (400 mg, 44%) as a yellow oil. 4-(4-amino-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka]

[0332] Step 2: A resealable reaction vial was charged with 4-(4-amino-7-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (380 mg, 1.04 mmol), imidazole (283 mg, 4.16 mmol), DMF (5 mL), and a stir bar. TBSCl (314 mg, 2.08 mmol) was added, and the solution was stirred at room temperature for 1 hour. The resulting mixture was purified by passage through a C18 column. Concentration in vacuo afforded 4-(4-amino-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (420 mg, 84%) as a yellow amorphous solid. 4-(4-amino-6-bromo-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide [ka]

[0333] Step 3: A round-bottom flask was charged with 4-(4-amino-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (400 mg, 0.84 mmol), dimethylformamide (5 mL), and a stir bar. NBS (225 mg, 1.00 mmol) was added, and the solution was stirred at room temperature for 1 hour. The reaction mixture was quenched with water and extracted with DCM. The organic phase was separated and dried over Na2SO4, filtered, and concentrated in vacuo. The crude material obtained was purified by silica gel chromatography. Concentration in vacuo afforded 4-(4-amino-6-bromo-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (450 mg, 94%) as a yellow amorphous solid. 6-{5-[2-(tert-butyldimethylsilyl)ethynyl]-3-methylpyrazin-2-yl}-7-methyl-5-{4-[(4-methylpyrimidin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0334] Step 4: A resealable reaction vial was charged with 4-(4-amino-6-bromo-7-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (200 mg, 0.36 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methacrylamide (124 mg, 0.43 mmol), Pd(dtbpf)Cl (23.4 mg, 36 μmol), CsF (164 mg, 1.08 mmol), 16:1 DMF:water (4 mL), and a stir bar, which was then evacuated and purged with nitrogen three times. The solution was stirred under N at 90° C. for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was collected, dried over Na2SO4, filtered, and concentrated in vacuo. The crude material was purified by Prep-HPLC (Column: XBridge Prep OBD C18 column, 19 × 250 mm, 5 μm; Mobile phase A: water (10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 20B to 50B in 8 min; 220 nm; RT: 7.23). Lyophilization afforded 4-(4-amino-7-(hydroxymethyl)-6-(4-methacrylamidophenyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2,2,2-trifluoroethyl)benzamide (30.4 mg, 16%) as an off-white amorphous solid.

[0335] Additional compounds prepared according to the method of Example 10 are illustrated in Table 9 below. [Table 9-1] [Table 9-2] Example 11 Scheme 9 [ka] 4-(4-amino-6-(4-methacrylamidophenyl)-7H-cyclopenta[d]pyrimidin-5-yl)benzoic acid methyl ester [ka]

[0336] Step 1: A round-bottom flask was charged with N-(4-{4-amino-5-bromo-7H-cyclopenta[d]pyrimidin-6-yl}phenyl)-2-methylprop-2-enamide (800 mg, 2.15 mmol), methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (731 mg, 2.79 mmol), Pd(dtbpf)Cl (139 mg, 215 μmol), CsF (980 mg, 6.45 mmol), DMF:HO=16:1 (8 mL), and a stir bar. The solution was stirred at 90 °C under N for 2 h. The reaction mixture was diluted with water (50 mL) and extracted three times with EtOAc (50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography and concentrated in vacuo to give methyl 4-{4-amino-6-[4-(2-methylprop-2-enamido)phenyl]-7H-cyclopenta[d]pyrimidin-5-yl}benzoate (600 mg, 56%) as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)-7H-cyclopenta[d]pyrimidin-5-yl)benzoic acid [ka]

[0337] Step 2: A round-bottom flask was charged with methyl 4-{4-amino-6-[4-(2-methylprop-2-enamido)phenyl]-7H-cyclopenta[d]pyrimidin-5-yl}benzoate (580 mg, 1.35 mmol), 2M THF:LiOH (6 mL) = 1:1, and a stir bar. The solution was stirred at room temperature for 3 h. The pH of the solution was adjusted to 6-7 with aqueous HCl. The product was precipitated by the addition of HCl and dried. This afforded 4-{4-amino-6-[4-(2-methylprop-2-enamido)phenyl]-7H-cyclopenta[d]pyrimidin-5-yl}benzoic acid (350 mg, 63%) as an off-white amorphous solid. 4-(4-amino-6-(4-methacrylamidophenyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)-N-(2-hydroxy-2-methylpropyl)benzamide [ka]

[0338] Step 3: A resealable reaction vial was charged with 4-{4-amino-6-[4-(2-methylprop-2-enamido)phenyl]-7aH-cyclopenta[d]pyrimidin-5-yl}benzoic acid (60 mg, 145 μmol), 1-amino-2-methylpropan-2-ol (15.5 mg, 174 μmol), HATU (55.2 mg, 145 μmol), DIEA (37.4 mg, 290 μmol), dimethylformamide (10 mL), and a stir bar. The mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with water and purified by HPLC (Column: XBridge Prep C18 OBD Column, 5 μm, 19 × 150 mm; Mobile Phase A: Water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow Rate: 25 mL / min; Gradient: 15B to 50B in 7 min; 254 / 220 nm; RT: 7.58). Lyophilization afforded 4-{4-amino-6-[4-(2-methylprop-2-enamido)phenyl]pyrrolo[2,1-f][1,2,4]triazin-5-yl}-N-(2-hydroxy-2-methylpropyl)benzamide (40.2 mg, 56.4%) as a white amorphous solid.

[0339] Additional compounds prepared according to the method of Example 11 are illustrated in Table 10 below. [Table 10-1] [Table 10-2] [Table 10-3] Example 12 Scheme 10 [ka] N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide [ka]

[0340] Step 1: A round-bottom flask was charged with 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (10 g, 42.8 mmol), prop-2-enoyl chloride (3.87 g, 42.8 mmol), pyridine (10.1 g, 128 mmol), dichloromethane (150 mL), and a stir bar. The solution was stirred at 0 °C for 1 h. The reaction mixture was quenched with water and extracted with DCM. The organic phase was dried over Na SO , filtered, and evaporated in vacuo. The crude material obtained was purified by silica gel chromatography. Concentration in vacuo afforded N-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (12 g, 98%) as a yellow oil. N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)acrylamide [ka]

[0341] Step 2: A round-bottom flask was charged with N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (1 g, 3.48 mmol), 5-bromo-6-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.22 g, 3.48 mmol), Pd(dppf)Cl (254 mg, 348 μmol), KPO (2.20 g, 10.4 mmol), DMF / HO (16:1) (15 mL), and a stir bar. The solution was stirred at 50 °C for 2 h. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine, dried over NaSO, filtered, and evaporated in vacuo. The crude material was purified by silica gel chromatography and concentrated in vacuo to give N-(4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)acrylamide (440 mg, 33%) as an off-white amorphous solid. (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)acrylamide [ka]

[0342] Step 3: A resealable reaction vial was charged with N-(4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3-methylphenyl)prop-2-enamide (200 mg, 517 μmol), 1-[(1R)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carbonyl]pyrrolidine (156 mg, 517 μmol), Pd(pddf)Cl (37.8 mg, 517 μmol), NaCO (164 mg, 1.55 mmol), DMF (10 mL), and a stir bar, which was then evacuated and purged with nitrogen three times. The mixture was stirred at 90° C. for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine, dried over Na2SO4, filtered, and evaporated in vacuo. The resulting crude material was purified by prep-HPLC (column: YMC-Actus Triart C18, 30 x 250, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 50 mL / min; gradient: 40B to 62B in 8 min; 220 nm; RT: 6.83). Lyophilization afforded (R)-N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)acrylamide (40 mg, 16%) as an off-white amorphous solid. (S)—N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)acrylamide [ka]

[0343] Step 4: A resealable reaction vial was charged with N-(4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-3-methylphenyl)prop-2-enamide (240 mg, 621 μmol), Pd(dppf)Cl (45.4 mg, 62.1 μmol), NaCO (197 mg, 1.86 mmol), 1-[(1S)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carbonyl]pyrrolidine (189240 mg, 621 μmol), dimethylformamide / HO (8 mL), and a stir bar, which was then evacuated and purged with nitrogen three times. The mixture was stirred at 90° C. for 2 hours. The reaction mixture was quenched with water and extracted with DCM. The organic phase was washed three times with brine, dried over Na2SO4, filtered, and evaporated in vacuo. The resulting crude material was purified by prep-HPLC (column: YMC-Actus Triart C18, 30 x 250, 5 μm; mobile phase A: water (10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 50 mL / min; gradient: 40B to 60B in 8 min; 220 nm; RT1: 7.67; RT2:; injection volume: ml; number of runs: ). Lyophilization afforded (S)—N-(4-(4-amino-7-methyl-5-(4-(pyrrolidine-1-carbonyl)cyclohex-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-methylphenyl)acrylamide (39 mg, 14%) as an off-white amorphous solid.

[0344] Additional compounds prepared according to the method of Example 12 are illustrated in Table 11 below. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4]

Table 11-5

Table 11-6

Table 11-7

Table 11-8

Table 11-9

Table 11-10

Table 11-11

Table 11-12

Table 11-13

Table 11-14

Table 11-15

Table 11-16

Table 11-17

Table 11-18

Table 11-19

Table 11-20

Table 11-21

Table 11-22

Table 11-23

Table 11-24

Table 11-25

Table 11-26

Table 11-27

Table 11-28

Table 11-29

Table 11-30

Table 11-31

Table 11-32

Table 11-33

Table 11-34

Table 11-35

Table 11-36

Table 11-37

[0345] Step 1: To a stirred solution / mixture of 2-(4-bromophenyl)propan-2-amine (1.50 g, 7.006 mmol) and TEA (2.13 g, 21.018 mmol) in DCM (30 mL) was added dropwise acryloyl chloride (0.63 g, 7.006 mmol) in portions at 0 °C under a nitrogen atmosphere. The mixture was stirred at 0 °C for 1 h. The resulting mixture was extracted with CHCl. ​​The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure to give N-(2-(4-bromophenyl)propan-2-yl)acrylamide (500 mg, 27%) as a yellow solid. N-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)acrylamide [ka]

[0346] Step 2: A solution / mixture of N-[2-(4-bromophenyl)propan-2-yl]prop-2-enamide (470.00 mg, 1.753 mmol), bis(pinacolato)diboron (667.63 mg, 2.629 mmol), AcOK (516.05 mg, 5.258 mmol), and Pd(dppf)Cl (128.25 mg, 0.175 mmol) in DMF (10 mL) was stirred at 80 °C under a nitrogen atmosphere for 2 h. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc=4 / 1 to give N-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-yl)acrylamide (400 mg, 72%) as an off-white solid. N-(2-(4-(4-amino-7-methyl-5-(4-(4-methylpyrimidin-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)propan-2-yl)acrylamide [ka]

[0347] Step 3: A solution / mixture of 6-iodo-7-methyl-5-[4-[(4-methylpyrimidin-2-yl)oxy]phenyl]pyrrolo[2,3-d]pyrimidin-4-amine (200.00 mg, 0.44 mmol), N-[2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-yl]prop-2-enamide (165.1 mg, 0.52 mmol), KPO (277.9 mg, 1.31 mmol), and Pd(dppf)Cl (31.9 mg, 0.04 mmol) in DMF (4 mL) and HO (1 mL) was stirred at 90 °C under a nitrogen atmosphere for 1 h. The resulting mixture was extracted with EtOAc. The combined organic layer was washed with brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by HPLC (Column: XBridge Shield RP18 OBD column, 5 μm, 19 × 150 mm; Mobile phase A: water (10 mM NH₄HCO₃), Mobile phase B: ACN; Flow rate: 25 mL / min; Gradient: 25B to 43B in 7 min; 220 / 254 nm; RT1: 6.25; RT2: ; Injection volume: ml; Run number: ). Lyophilization afforded N-(2-(4-(4-amino-7-methyl-5-(4-(4-methylpyrimidin-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)propan-2-yl)acrylamide (51 mg, 22.3%) as an off-white amorphous solid.

[0348] Additional compounds prepared according to the method of Example 13 are illustrated in Table 12 below. [Table 12-1] [Table 12-2] [Table 12-3] [Table 12-4] [Table 12-5]

Table 12-6

Table 12-7

Table 12-8

Table 12-9

Table 12-10

Table 12-11

Table 12-12

Table 12-13

Table 12-14

Table 12-15

Table 12-16

Table 12-17

Table 12-18

Table 12-19

Table 12-20

Table 12-21

[0349] Step 1: A resealable reaction vial was charged with tert-butyl 3-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-2,5-dihydro-1H-pyrrole-1-carboxylate (1.2 g, 3.07 mmol), Pd—C (120 mg, 1.2 mol), and a stir bar, then evacuated and purged with hydrogen three times. MeOH (20 mL) was added, and the mixture was stirred at 50° C. overnight. The reaction mixture was filtered through a pad of Celite®, the pad was washed with water, and the filtrate was concentrated in vacuo to afford tert-butyl 3-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidine-1-carboxylate (0.9 g, 91.8%) as an off-white solid. tert-Butyl 3-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidine-1-carboxylate [ka]

[0350] Step 2: A round-bottom flask was charged with tert-butyl 3-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidine-1-carboxylate (300 mg, 945 μmol), NBS (168 mg, 945 μmol), and a stir bar. Dichloromethane (5 mL) was added, and the solution was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford tert-butyl 3-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidine-1-carboxylate (230 mg, 61.4%) as a light yellow solid. tert-Butyl 3-(4-amino-7-methyl-5-(4-(pyrimidin-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidine-1-carboxylate [ka]

[0351] Step 3: A resealable reaction vial was charged with tert-butyl 3-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidine-1-carboxylate (200 mg, 504 μmol), 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrimidine (165 mg, 554 μmol), Pd(dtbpf)Cl (32.8 mg, 50.4 μmol), KPO (320 mg, 1.51 mmol), and a stir bar, then evacuated and purged with nitrogen three times. DMF / water (2 mL) was added, and the mixture was stirred at 90° C. for 2 hours. The reaction mixture was diluted with water (10 mL), and the aqueous phase was extracted three times with dichloromethane (10 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The crude material was purified by silica gel chromatography (5 g column; eluted with dichloromethane / methanol / 0.1% triethylamine; ratio). Concentration in vacuo afforded tert-butyl 3-{4-amino-7-methyl-5-[4-(pyrimidin-2-yloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidine-1-carboxylate (100 mg, 40.7%) as a light brown solid. 7-Methyl-5-(4-(pyrimidin-2-yloxy)phenyl)-6-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0352] Step 4: A round-bottom flask was charged with tert-butyl 3-{4-amino-7-methyl-5-[4-(pyrimidin-2-yloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidine-1-carboxylate (200 mg, 410 μmol) and a stir bar. TFA / DCM (1 / 4 mL) was added, and the solution was stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo. It was then dissolved in saturated NaHCO and extracted three times with DCM. The combined organic layers were dried over anhydrous NaSO. Filtration and evaporation afforded 7-methyl-5-[4-(pyrimidin-2-yloxy)phenyl]-6-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (150 mg, 94.4%) as an off-white solid. 1-(3-(4-amino-7-methyl-5-(4-(pyrimidin-2-yloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)pyrrolidin-1-yl)prop-2-en-1-one [ka]

[0353] Step 5: A round-bottom flask was charged with 7-methyl-5-[4-(pyrimidin-2-yloxy)phenyl]-6-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (50 mg, 129 μmol), TEA (39.0 mg, 387 μmol), dichloromethane (4 mL), and a stir bar. Prop-2-enoyl chloride (10.4 mg, 116 μmol) was added at −30° C., and the solution was stirred at −30° C. for 30 minutes. The reaction mixture was filtered through a pad of Celite®, the pad was washed with DCM, and the filtrate was concentrated under reduced pressure. The crude material obtained was purified by HPLC (acetonitrile / water / 0.1% formic acid). Lyophilization afforded 1-(3-{4-amino-7-methyl-5-[4-(pyrimidin-2-yloxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrrolidin-1-yl)prop-2-en-1-one (5.92 mg, 11.6% 1) as a white amorphous solid.

[0354] Additional compounds prepared according to the method of Example 14 are illustrated in Table 13 below. [Table 13-1] [Table 13-2] [Table 13-3] [Table 13-4] [Table 13-5] [Table 13-6] [Table 13-7] [Table 13-8] [Table 13-9] [Table 13-10] [Table 13-11] [Table 13-12] [Table 13-13] [Table 13-14] [Table 13-15] [Table 13-16]

Table 13-17

Table 13-18

Table 13-19

Table 13-20

Table 13-21

Table 13-22

Table 13-23

Table 13-24

Table 13-25

Table 13-26

Table 13-27

Table 13-28

Table 13-29

Table 13-30

Table 13-31

Table 13-32

Table 13-33

Table 13-34

Table 13-35

Table 13-36

Table 13-37

Table 13-38

Table 13-39

Table 13-40

Table 13-41

Table 13-42

Table 13-43

Table 13-44

Table 13-45

Table 13-46

change

[0355] Step 1: A round-bottom flask was charged with 4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (1.7 g, 10.18 mmol), THF (30 mL), and a stir bar. LDA (7.63 mL, 15.26 mmol, 2 M) was added dropwise to the above solution at -78 °C. After stirring at the same temperature for 1 hour, (S)-tert-butyl 2-methyl-4-oxopyrrolidine-1-carboxylate (4.05 g, 20.35 mmol) in THF (10 mL) was added at -78 °C, and the mixture was warmed to room temperature for 1 hour. The mixture was quenched with sat. NH4Cl (10 mL) and extracted three times with EtOAc (40 mL). The combined organic phases were washed with brine, dried over Na2SO4, and combined under reduced pressure. The resulting crude product was purified by silica gel chromatography (eluting with PE / EtOAc = 2:1) to give tert-butyl (2S)-4-(4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate (550 mg, 1.50 mmol, 15%) as an off-white solid. tert-Butyl (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate [ka]

[0356] Step 2: A 50 mL unsealed tube was charged with tert-butyl (2S)-4-(4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate (550 mg, 1.50 mmol), NH3 / HO (10 mL, 25%-30%), and 1,4-dioxane (10 mL), the tube was sealed, and the mixture was stirred at 100 °C for 12 h. The tube was cooled to room temperature, and the mixture was poured off, the solvent was concentrated, and the crude product was washed three times with DCM (100 mL) and concentrated to give tert-butyl (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate (400 mg, 77%) as an off-white solid. (S)-7-Methyl-6-(5-methyl-2,5-dihydro-1H-pyrrol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0357] Step 3: A round-bottom flask was charged with tert-butyl (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-hydroxy-2-methylpyrrolidine-1-carboxylate (380 mg, 1.09 mmol), HCl (5 mL), and a stir bar. The mixture was stirred at 100° C. for 2 h. After cooling to room temperature, the mixture was concentrated and diluted with water (10 mL), the pH was adjusted to 7-8, and extracted three times with DCM (20 mL). The organic phases were combined and concentrated under reduced pressure to give crude (S)-7-methyl-6-(5-methyl-2,5-dihydro-1H-pyrrol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (330 mg) as a brown solid. 7-Methyl-6-((5S)-5-methylpyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0358] Step 4: A resealable reaction vial was charged with (S)-7-methyl-6-(5-methyl-2,5-dihydro-1H-pyrrol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (330 mg, crude), Pd / C (30 mg), MeOH (10 mL), and a stir bar. The mixture was evacuated and purged with nitrogen three times, then evacuated and purged with hydrogen five times. The mixture was stirred at 50° C. overnight. The mixture was then filtered, the filter cake was washed five times with MeOH, and the organic phase was concentrated to give 7-methyl-6-((5S)-5-methylpyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (220 mg, 63% over two steps) as a brown solid. tert-Butyl (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidine-1-carboxylate [ka]

[0359] Step 5: A round-bottom flask was charged with 7-methyl-6-((5S)-5-methylpyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (220 mg, 0.95 mmol), TEA (288 mg, 2.85 mmol), MeOH (5 mL), and a stir bar. BocO (308 mg, 1.42 mmol) was added, and the solution was stirred at room temperature for 12 h. The mixture was diluted with water (10 mL) and extracted three times with DCM (50 mL). The organic phases were combined and washed with brine, dried over Na2SO4, concentrated in vacuo, and the crude product was purified by prep-TLC with DCM / MeOH (20:1) to afford tert-butyl (2S)-4-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidine-1-carboxylate (190 mg, 60%) as a brown solid. tert-Butyl (2S)-4-(4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidine-1-carboxylate [ka]

[0360] Step 6: A round-bottom flask was charged with tert-butyl (2S)-4-{4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-2-methylpyrrolidine-1-carboxylate (180 mg, 543 μmol), dimethylformamide (15 mL), and a stir bar. NBS (101 mg, 570 μmol) was added, and the solution was stirred at 0° C. for 1 hour. The mixture was diluted with DCM (50 mL), washed with water and brine, dried over anhydrous NaSO, and concentrated under reduced pressure. The crude product was purified by prep-TLC using DCM:MEOH (12:1) to afford tert-butyl (2S)-4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-2-methylpyrrolidine-1-carboxylate (200 mg, 85%) as a brown solid. tert-Butyl (2S)-4-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidine-1-carboxylate [ka]

[0361] Step 7: A resealable reaction vial was charged with tert-butyl (2S)-4-{4-amino-5-bromo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl}-2-methylpyrrolidine-1-carboxylate (200 mg, 487 μmol), 2-methyl-6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyridine (181 mg, 584 μmol), KPO (309 mg, 1.46 mmol), Pd(DtBPF)Cl (47.5 mg, 73.0 μmol), and a stir bar, which was then evacuated and purged with nitrogen three times. DMF:water (16:1) (10 mL) was added, and the solution was stirred at 90 °C for 1 hour. The mixture was diluted with EtOAc (50 mL) and washed three times each with water and brine. The organic phase was dried over anhydrous NaSO and concentrated under reduced pressure. The crude product was purified by C18 flash chromatography to give tert-butyl (2S)-4-(4-amino-7-methyl-5-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidine-1-carboxylate (140 mg, 56%) as a light brown oil. 7-Methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-6-((5S)-5-methylpyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0362] Step 8: A round-bottom flask was charged with tert-butyl (2S)-4-(4-amino-7-methyl-5-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidine-1-carboxylate (140 mg, 272 μmol), TFA / DCM (1:4 v / v, 15 mL), and a stir bar. The solution was stirred at room temperature for 3 hours. The solvent was removed, and the crude product was diluted with DCM and the pH was adjusted to 7 with NaCO aq. The organic phase was concentrated to give 7-methyl-5-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-6-[(5S)-5-methylpyrrolidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (90.0 mg, 100%), which was used in the next step without purification. 1-((2S)-4-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidin-1-yl)prop-2-en-1-one [ka]

[0363] Step 9: A round-bottom flask was charged with TEA (65.7 mg, 651 μmol), prop-2-enoyl chloride (15.6 mg, 173 μmol), 7-methyl-5-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-6-[(5S)-5-methylpyrrolidin-3-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (90.0 mg, 217 μmol), and a stir bar. Dichloromethane (5 mL) was added, and the solution was stirred at −65° C. for 0.5 h. The mixture was quenched with MeOH and concentrated. The crude product was purified by prep-HPLC (column: XBridge Shield RP18 OBD column, 30×150 mm, 5 μm; mobile phase A: water (10 mmol / L) NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 25B to 50B in 8 min; 220 nm; RT 1:7.23) to afford 1-[(2S)-4-(4-amino-7-methyl-5-{4-[(6-methylpyridin-2-yl)oxy]phenyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-2-methylpyrrolidin-1-yl]prop-2-en-1-one (38.3 mg, 38%) as a white solid.

[0364] Additional compounds prepared according to the method of Example 15 are illustrated in Table 14 below. [Table 14-1] [Table 14-2] [Table 14-3] [Table 14-4] [Table 14-5] Example 16 Scheme 13 [ka] tert-Butyl 3-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-fluoropyrrolidine-1-carboxylate [ka]

[0365] Step 1: A round-bottom flask was charged with tert-butyl 3-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-hydroxypyrrolidine-1-carboxylate (200 mg, 0.39 mmol), DCM (10 mL), and a stir bar. DAST (74.8 mg, 0.46 mmol) was added, and the solution was stirred at 0° C. for 3 h. The reaction mixture was quenched with water, extracted with DCM, dried over NaSO, and concentrated in vacuo. The resulting crude material was purified by silica gel chromatography. Concentration in vacuo afforded tert-butyl 3-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-fluoropyrrolidine-1-carboxylate (127 mg, 63%) as a yellow solid. 6-(4-fluoropyrrolidin-3-yl)-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine [ka]

[0366] Step 2: A resealable reaction vial was charged with tert-butyl 3-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-fluoropyrrolidine-1-carboxylate (127 mg, 0.24 mmol), DCM (5 mL), and a stir bar. TFA (2 mL) was added, and the solution was stirred at 25° C. for 1 hour. The reaction mixture was concentrated, diluted with water, adjusted to a pH of 7 with Sat. NaCO, extracted with DCM, dried over NaSO, and concentrated in vacuo. The crude material obtained was purified by prep-TLC. Concentration in vacuo afforded 6-(4-fluoropyrrolidin-3-yl)-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (77 mg, 77%) as a brown solid. 1-(3-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-fluoropyrrolidin-1-yl)prop-2-en-1-one [ka]

[0367] Step 3: A round-bottom flask was charged with 6-(4-fluoropyrrolidin-3-yl)-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (77 mg, 180 μmol), TEA (55.8 mg, 0.55 mmol), DCM (5 mL), and a stir bar. Acryloyl chloride (13.2 mg, 147 μmol) was added, and the solution was stirred at −35° C. for 0.5 h. The reaction mixture was quenched with MeOH, the resulting mixture was concentrated, and the crude material was purified by prep-HPLC. Lyophilization afforded 1-(3-(4-amino-7-methyl-5-(4-((6-methylpyridin-2-yl)oxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-4-fluoropyrrolidin-1-yl)prop-2-en-1-one (5.2 mg, 6%) as a white amorphous solid.

[0368] Additional compounds prepared according to the method of Example 16 are illustrated in Table 15 below. [Table 15] Example 17 Scheme 14 [ka] tert-Butyl 3-(4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-hydroxypyrrolidine-1-carboxylate [ka]

[0369] Step 1: A resealable reaction vial was charged with 4-chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (5 g, 29.9 mmol), tetrahydrofuran (200 mL), and a stir bar, then evacuated and purged with nitrogen three times. LDA (30 mL, 59.9 mmol) was added dropwise at −78° C., and the mixture was stirred at −78° C. for 30 minutes. tert-Butyl 3-oxopyrrolidine-1-carboxylate (17 g, 89.8 mmol) in 100 mL of THF was added dropwise, and the mixture was stirred at −78° C. for 1 hour. The mixture was warmed to room temperature, and the reaction mixture was diluted with HO (300 mL), and the aqueous phase was extracted three times with EA (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting crude material was purified by silica gel chromatography (eluting with PE / EA=10 / 1) and concentrated in vacuo to give tert-butyl 3-(4-chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-hydroxypyrrolidine-1-carboxylate (2.20 g, 20.9%) as a light yellow solid. tert-Butyl 3-(4-chloro-5-iodo-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)-3-hydroxypyrrolidine-1-carboxylate [ka]

[0370] Step 2: A round-bottom flask was charged with tert-but...

Claims

1. Formula I-1: 【Chemistry 471】 or a pharma- ceutically acceptable salt thereof, in formula I-1: Cy A is 【Chemistry 472】 where 【Chemistry 473】 represents a bond to R 5 , and 【Chemical 474】 represents a bond to Cy6; R 5 is -R 5A -L 5 -R 5B ; R 5A is a divalent radical of R B where R 5A is substituted with m instances of R 5C in addition to -L 5 -R 5B ; R 5B is R B or hydrogen, where R 5B is substituted with n instances of R 5D ; Cy 6 is phenylene; a divalent saturated or partially unsaturated 3- to 14-membered carbocyclic ring; a divalent saturated or partially unsaturated 3- to 14-membered heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 5- to 14-membered heteroarylene having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; where Cy 6 is substituted with p instances of R 6 in addition to -L 6 -R w ; R W is 【Chemistry 491】 and each instance of R 6 is independently R A or R B , where R 6 is substituted with q instances of R C ; or two instances of R 6 , one instance of R 6 and one instance of R L , one instance of R 6 and one instance of R WA , or one instance of R 6 and one instance of R 7a together with the atoms therebetween form a 4- to 8-membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is substituted with r instances of R C ; R 7 is R B or H, where R 7 is substituted with t instances of R 7A ; R 8 is -NR 2 , H, halogen, -OH, or C 1-6 aliphatic optionally substituted with 1-3 halogens; R 9 is H, —NR 2 , halogen, or C 1-6 aliphatic optionally substituted with 1-3 halogens; R 10 is H or C 1-6 aliphatic optionally substituted with 1-3 halogens; L 5 is —O—, a covalent bond, or a C 1-4 divalent saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units of the chain are independently —CH(R L )—, —C(R L ) 2 —, C 3-6 cycloalkylene, 3- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, —NH—, —NHC(O)—, —N(R L )—, —NHC(O)—, —N(R L )C(O)—, —C(O)NH—, —C(O)N(R L )—, —NHS(O) 2 —, —N(R L )S(O) 2 —, —S(O) 2 NH—, —S(O) 2 N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 -; wherein each of said C 3-6 cycloalkylene, 3- to 6-membered heterocycloalkylene, and 5- to 6-membered heteroarylene is optionally substituted with one instance of R A or a C 1-6 aliphatic; L 6 is a C 1-4 divalent saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units of the chain are independently -NH-, -NHC(O)-, -CH(R L )-, -C(R L ) 2 -, C 3-6 cycloalkylene, 3- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -N(R L )-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O) 2 -, -N(R L )S(O) 2 -, -S(O) 2 NH-, -S(O) 2 N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 -; wherein said C 3-6 cycloalkylene, 3- to 6-membered heterocycloalkylene, and 5- to 6-membered heteroarylene are each optionally substituted with one instance of R A or a C 1-6 aliphatic; or L 6 is a covalent bond; each of R WA , R WB , and R WC is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or one instance of R WA and R WB , one instance of R WB and R WC , one instance of R WA and R L , or one instance of R WC and R L , taken together with the atoms therebetween, form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is substituted with w instances of R C ; R WD is halogen or -OS(O) 2 R; each instance of R 5C , R 5D , R 7A , and R L is independently R A or R B and is substituted with u instances of R C ; or two instances of R 5C , one instance of R 5C and one instance of R 5D , or two instances of R 5D together with the atoms therebetween form a 3- to 7-membered saturated, partially unsaturated, or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is substituted with v instances of R C ; each instance of R A is independently halogen, oxo, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -S(O)NR 2 , -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)C(NR)NR 2 , -N(R)S(O) 2 NR 2 , or -N(R)S(O) 2 R; Each instance of R B is independently phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a C 1-6 aliphatic; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each instance of R C is independently oxo, halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —S(O)NR 2 , —S(O) 2 F, —OS(O) 2 F, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)C(NR)NR 2 , —N(R)S(O) 2 NR 2 , —N(R)S(O) 2 NR 2 , or —N(R)S(O) 2 . R, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each of m, n, p, q, r, t, u, v, and w is independently 0, 1, 2, 3, or 4; wherein the compound is 【Chemistry 492】 isn't it, A compound or a pharma- ceutically acceptable salt thereof.

2. Cy A is 【Chemistry 476】 2. The compound of claim 1 ,

3. Formula I: 【Chemistry 477】 or a pharma- ceutically acceptable salt thereof, wherein in formula I: R 5 is -R 5A -L 5 -R 5B ; R 5A is a divalent radical of R B where R 5A is substituted with m instances of R 5C in addition to -L 5 -R 5B ; R 5B is R B or hydrogen, where R 5B is substituted with n instances of R 5D ; Cy 6 is phenylene or a 6-membered heteroarylene having 1 to 3 nitrogen atoms, where Cy 6 is substituted with p instances of R 6 in addition to -L 6 -R w ; R W is 【Chemistry 493】 and each instance of R 6 is independently R A or R B , where R 6 is substituted with q instances of R C ; or two instances of R 6 , or one instance of R 6 and one instance of R L , taken together with the atoms therebetween, form a 4- to 7-membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is substituted with r instances of R C ; R 7 is R B or H, where R 7 is substituted with t instances of R 7A ; L 5 is —O—, a covalent bond, or a C 1-4 divalent saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units of the chain are independently —CH(R L )—, —C(R L ) 2 —, C 3-6 cycloalkylene, 3- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, —NH—, —NHC(O)—, —N(R L )—, —NHC(O)—, —N(R L )C(O)—, —C(O)NH—, —C(O)N(R L )—, —NHS(O) 2 —, —N(R L )S(O) 2 —, —S(O) 2 NH—, —S(O) 2 N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 -; wherein each of said C 3-6 cycloalkylene, 3- to 6-membered heterocycloalkylene, and 5- to 6-membered heteroarylene is optionally substituted with one instance of R A or a C 1-6 aliphatic; L 6 is a C 1-4 divalent saturated or unsaturated, straight or branched hydrocarbon chain, wherein one or two methylene units of the chain are independently selected from -NH-, -NHC(O)-, -CH(R L )-, -C(R L ) 2 -, C 3-5 cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -N(R L )-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O) 2 -, -N(R L )S(O) 2 -, -S(O) 2 NH-, -S(O) 2 N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 -; or L 6 is a covalent bond; each of R WA , R WB , and R WC is independently hydrogen, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or one instance of R WA and R WB , one instance of R WB and R WC , one instance of R WA and R L , or one instance of R WC and R L , taken together with the atoms therebetween, form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O) 2 R; each instance of R 5C , R 5D , R 7A , and R L is independently R A or R B and is substituted with u instances of R C ; each instance of R A is independently halogen, oxo, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -S(O)NR 2 , -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)C(NR)NR 2 , -N(R)S(O) 2 NR 2 , or -N(R)S(O) 2 R; Each instance of R B is independently phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a C 1-6 aliphatic; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each instance of R C is independently oxo, halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —S(O)NR 2 , —S(O) 2 F, —OS(O) 2 F, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)C(NR)NR 2 , —N(R)S(O) 2 NR 2 , —N(R)S(O) 2 NR 2 , or —N(R)S(O) 2 . R, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4; wherein the compound is 【Chemistry 494】 isn't it, A compound or a pharma- ceutically acceptable salt thereof.

4. -Cy 6 -L 6 -R W taken together is: 【Chemical 479】 The compound according to any one of claims 1 to 3,

5. R 5 is: 【Chemistry 480】 The compound according to any one of claims 1 to 4,

6. R 5 is: 【Chemistry 481】 The compound according to any one of claims 1 to 4,

7. Formula X-1, XI-1, XII-1, or XIII-1: 【Chemistry 482】 or a pharma- ceutically acceptable salt thereof, wherein in formulas X-1, XI-1, XII-1, and XIII-1: Cy A is 【Chemistry 483】 where Cy A 【Chemistry 484】 teeth, 【Chemistry 485】 represents binding to Cy A 【Chemistry 486】 teeth, 【Chemistry 487】 represents a bond to R 5B is R B or hydrogen, where R 5B is substituted with n instances of R 5D ; R W is 【Chemistry 495】 and each instance of R 6 is independently R A or R B , where R 6 is substituted with q instances of R C ; or two instances of R 6 , or one instance of R 6 and one instance of R L , taken together with the atoms therebetween, form a 4- to 7-membered partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the ring is substituted with r instances of R C ; R 7 is R B or H, where R 7 is substituted with t instances of R 7A ; R 8 is -NR 2 , H, halogen, -OH, or C 1-6 aliphatic optionally substituted with 1-3 halogens; R 9 is H, —NR 2 , halogen, or C 1-6 aliphatic optionally substituted with 1-3 halogens; R 10 is H or C 1-6 aliphatic optionally substituted with 1-3 halogens; L 5 is a C 1-4 divalent saturated or unsaturated, straight or branched hydrocarbon chain, where one or two methylene units of the chain are independently -O-, -CH(R L )-, -C(R L ) 2 -, C 3-5 cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -NH-, -N(R L )-, -NHC(O)-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O) 2 -, -N(R L )S(O) 2 -, -S(O) 2 NH-, -S(O) 2 N(R L )-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 -; or is a covalent bond; L 6 is a C 1-4 divalent saturated or unsaturated, straight or branched hydrocarbon chain, wherein one or two methylene units of the chain are independently selected from -NH-, -NHC(O)-, -CH(R L )-, -C(R L ) 2 -, C 3-5 cycloalkylene, 3- to 5-membered heterocycloalkylene, 5- to 6-membered heteroarylene, -N(R L )-, -N(R L )C(O)-, -C(O)NH-, -C(O)N(R L )-, -NHS(O) 2 -, -N(R L )S(O) 2 -, -S(O) 2 NH-, -S(O) 2 N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O) 2 -; or L 6 is a covalent bond; each of R WA , R WB , and R WC is independently hydrogen, deuterium, halogen, -CN, -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or one instance of R WA and R WB , one instance of R WB and R WC , one instance of R WA and R L , or one instance of R WC and R L , taken together with the atoms therebetween, form a 4- to 7-membered saturated or partially unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; R WD is halogen or -OS(O) 2 R; each instance of R 5C , R 5D , R 7A , and R L is independently R A or R B and is substituted with u instances of R C ; each instance of R A is independently halogen, oxo, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -S(O)NR 2 , -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)C(NR)NR 2 , -N(R)S(O) 2 NR 2 , or -N(R)S(O) 2 R; Each instance of R B is independently phenyl; a 5- to 6-membered monocyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a C 1-6 aliphatic; an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 3- to 7-membered saturated or partially unsaturated carbocyclic ring; a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 7- to 12-membered saturated or partially unsaturated bicyclic heterocyclic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each instance of R C is independently oxo, halogen, —CN, —NO 2 , —OR, —SR, —NR 2 , —S(O) 2 R, —S(O) 2 NR 2 , —S(O)R, —S(O)NR 2 , —S(O) 2 F, —OS(O) 2 F, —C(O)R, —C(O)OR, —C(O)NR 2 , —C(O)N(R)OR, —OC(O)R, —OC(O)NR 2 , —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR 2 , —N(R)C(NR)NR 2 , —N(R)S(O) 2 NR 2 , —N(R)S(O) 2 NR 2 , or —N(R)S(O) 2 . R, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Each R is independently hydrogen or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated heterocyclic rings having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered heteroaryl rings having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen, together with the atoms between them, form a 4- to 7-membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; and Each of m, n, p, q, r, t, and u is independently 0, 1, 2, 3, or 4; wherein the compound is 【Chemistry 496】 isn't it, A compound or a pharma- ceutically acceptable salt thereof.

8. R W is 【Chemistry 489】 The compound according to any one of claims 1 to 7,

9. R W is 【Chemistry 490】 The compound according to any one of claims 1 to 7, 10. The compound according to any one of claims 1 to 9, wherein L 6 is -NH-.

11. The compound of formula I has the formula II, III, IV, V, VI, VII, VIII, or IX: 【Chemistry 497】 2. The compound of claim 1, selected from:

12. The compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from the compounds depicted in Table 1.

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier.

14. A composition comprising a compound according to any one of claims 1 to 12 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 13, for inhibiting FGFR2 signaling activity in a subject in need thereof.

15. A composition comprising a compound according to any one of claims 1 to 12 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 13, for treating an FGFR2-mediated disorder in a subject in need thereof.

16. A composition comprising a compound according to any one of claims 1 to 12 or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to claim 13, for treating a disorder in a subject in need thereof, wherein the disorder is bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, ovarian cancer, rectal cancer, endometrial cancer, or urothelial cancer.

17. The composition described in claim 16, wherein the disorder is bile duct cancer.

18. The composition described in claim 17, wherein the cholangiocarcinoma is intrahepatic cholangiocarcinoma.

19. The composition described in claim 16, wherein the disorder is liver cancer.

20. The composition described in claim 19, wherein the liver cancer is hepatocellular carcinoma.

21. The composition described in claim 16, wherein the disorder is lung cancer.

22. The composition described in claim 21, wherein the lung cancer is squamous cell lung cancer or non-small cell lung cancer.

Citation Information

Patent Citations

  • 4-Amino-6-(3-(3-bromophenyl)phenyl)-5-cyano-7-(β-L-furanoxose)pyrrolo[2,3-d]pyrimidine, its derivatives, and their use in the preparation of antitumor drugs.

    CN102286048A

  • Use of pyrazolopyrazine as an adenosine antagonist

    JP2003515537A

  • Furo- and thienopyrimidine derivatives as angiogenesis inhibitors

    JP2005508904A

  • Azaindole kinase inhibitor

    JP2005538990A

  • Pyrazolopyridine and methods of making and using same

    JP2006502165A